Original Article
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
N Engl J Med 2006; 354:1706-1717April 20, 2006
- Abstract
Background
Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events.
Methods
We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes.
Results
The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspirin and 7.3 percent with placebo plus aspirin (relative risk, 0.93; 95 percent confidence interval, 0.83 to 1.05; P=0.22). The respective rate of the principal secondary efficacy end point, which included hospitalizations for ischemic events, was 16.7 percent and 17.9 percent (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.995; P=0.04), and the rate of severe bleeding was 1.7 percent and 1.3 percent (relative risk, 1.25; 95 percent confidence interval, 0.97 to 1.61 percent; P=0.09). The rate of the primary end point among patients with multiple risk factors was 6.6 percent with clopidogrel and 5.5 percent with placebo (relative risk, 1.2; 95 percent confidence interval, 0.91 to 1.59; P=0.20) and the rate of death from cardiovascular causes also was higher with clopidogrel (3.9 percent vs. 2.2 percent, P=0.01). In the subgroup with clinically evident atherothrombosis, the rate was 6.9 percent with clopidogrel and 7.9 percent with placebo (relative risk, 0.88; 95 percent confidence interval, 0.77 to 0.998; P=0.046).
Conclusions
In this trial, there was a suggestion of benefit with clopidogrel treatment in patients with symptomatic atherothrombosis and a suggestion of harm in patients with multiple risk factors. Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes. (ClinicalTrials.gov number, NCT00050817.)
Media in This Article
Figure 1
Cumulative Incidence of the Primary End Point (Panel A) and of the Secondary End Point (Panel B).Figure 2
Hazard Ratios for Myocardial Infarction (MI), Stroke, or Death from Cardiovascular Causes in Each of the Subgroups Examined.Article Activity
- Article
Atherosclerotic vascular disease has a propensity to engender arterial thrombosis, a sequence that has been characterized as an “atherothrombotic” process.1,2 Collectively, atherothrombotic disorders of the coronary, cerebrovascular, and peripheral arterial circulation are the leading cause of death and disability in the world.3 Their prevalence is increasing; they are significantly undertreated, and better means of prevention are needed.4
Platelets have been shown to play a central role in the pathogenesis of atherothrombosis.1,2 Low-dose aspirin has been shown to reduce ischemic outcomes in patients above a certain risk threshold.5 However, aspirin alone in many instances is not sufficient to prevent ischemic events in patients at high risk. Furthermore, aspirin inhibits only the cyclooxygenase pathway, leaving the adenosine diphosphate P2Y12 receptor unaffected. Dual antiplatelet therapy with clopidogrel (Plavix, Sanofi-Aventis), a P2Y12-receptor antagonist, plus aspirin has been shown to reduce ischemic events in patients with unstable angina, myocardial infarction without ST-segment elevation, or myocardial infarction with ST-segment elevation, as well as those undergoing angioplasty and stenting.6-9
Accordingly, we tested the hypothesis that long-term treatment with a combination of clopidogrel plus aspirin may provide greater protection against cardiovascular events than aspirin alone in a broad population of patients at high risk.
Methods
Trial Design
The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial was a prospective, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of clopidogrel plus aspirin as compared with aspirin alone in patients at high risk for a cardiovascular event. The details of the trial design have been published previously.10 The trial was approved by the institutional ethics committee of each participating institution as well as the appropriate national ethics committees.
The trial was designed by Dr. Topol, who was responsible for obtaining funding and executing the trial, and it was planned and conducted by the executive committee, with extensive review of the data for its interpretation. The trial was managed by the Cleveland Clinic Cardiovascular Coordinating Center and by the national coordinators in each country in which patients were enrolled. Data collection and entry were performed by the sponsor and cosponsor. The locked, cleaned database was transferred to the Cleveland Clinic Cardiovascular Coordinating Center, where data analysis was performed. Dr. Bhatt prepared the first draft of the manuscript, and the executive committee helped to revise it. Dr. Topol had full access to an independent database for any query regarding the analyses and assumes responsibility for the integrity of the data.
Funding for the CHARISMA trial was provided by Sanofi-Aventis and Bristol-Myers Squibb. The sponsor and cosponsor had advisory input in the design of the study, had nonvoting input in the executive committee, and were responsible for auditing at individual study sites. The executive committee bears complete responsibility for the analysis of the results, the veracity and completeness of the reporting, and the writing of the manuscript; the sponsors did have the opportunity to review the manuscript.
Patients
Patients were eligible to enroll in the trial if they were 45 years of age or older and had one of the following conditions: multiple atherothrombotic risk factors, documented coronary disease, documented cerebrovascular disease, or documented symptomatic peripheral arterial disease. The inclusion criteria for those with multiple risk factors and for those with established vascular disease are shown in Table 1Table 1
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease..Patients were excluded from the trial if they were taking oral antithrombotic medications or nonsteroidal antiinflammatory drugs on a long-term basis (although cyclooxygenase-2 inhibitors were permitted). Patients were also excluded if, in the judgment of the investigator, they had established indications for clopidogrel therapy (such as a recent acute coronary syndrome). Patients who were scheduled to undergo a revascularization were not allowed to enroll until the procedure had been completed; such patients were excluded if they were considered to require clopidogrel after revascularization.
Trial Procedures
After providing written informed consent, patients were randomly assigned either to clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or to placebo plus low-dose aspirin. Study-drug assignment was performed centrally by an interactive voice-response system on the basis of a preestablished randomization scheme, stratified according to site. All patients also received standard therapy as appropriate (e.g., statins or beta-blockers) at the discretion of the investigator and other responsible clinicians. The use of appropriate background therapy was emphasized to the investigators, who were provided with international guidelines.
Follow-up evaluations were performed at one month, three months, and six months and every six months thereafter until the end of the trial. At these visits, patients' compliance was assessed, standard medication was adjusted as appropriate, and all interventions, outcome events, and adverse events were recorded. According to the power calculations described below and the event-driven design of the trial, all patients were followed until a common study end date based on the prespecified target of 1040 primary efficacy end points was reached.
End Points
All primary trial end points were adjudicated by the clinical events committee, whose members were unaware of patients' treatment assignments. The primary efficacy end point was the first occurrence of myocardial infarction, stroke (of any cause), or death from cardiovascular causes (including hemorrhage). The principal secondary efficacy end point was the first occurrence of myocardial infarction, stroke, death from cardiovascular causes, or hospitalization for unstable angina, a transient ischemic attack, or a revascularization procedure (coronary, cerebral, or peripheral). Other efficacy end points included death from any cause and death from cardiovascular causes as well as myocardial infarction, ischemic stroke, any stroke, and hospitalization for unstable angina, transient ischemic attack, or revascularization, considered separately.
The primary safety end point was severe bleeding, according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition, which includes fatal bleeding and intracranial hemorrhage, or bleeding that caused hemodynamic compromise requiring blood or fluid replacement, inotropic support, or surgical intervention.11 Moderate bleeding according to the GUSTO criteria (bleeding that led to transfusion but did not meet the criteria for severe bleeding) was also examined, as were fatal bleeding and primary intracranial hemorrhage.
Analyses of the primary end point were also performed in several prospectively defined subgroups. The subgroups included symptomatic patients (defined as patients enrolled on the basis of established cardiovascular disease) as compared with asymptomatic patients (those enrolled on the basis of multiple atherothrombotic risk factors), as well as patients with and those without a history of diabetes, hypertension, hypercholesterolemia, peripheral arterial disease, prior cardiac or vascular surgery, prior myocardial infarction, prior stroke, prior transient ischemic attack, or prior use of other antiplatelet agents, angiotensin-converting–enzyme (ACE) inhibitors (overall and ramipril vs. other ACE inhibitors), statins (overall and atorvastatin, simvastatin, and pravastatin), beta-blockers, calcium antagonists, antidiabetic agents, angiotensin II–receptor blockers, cyclooxygenase-2 inhibitors, and anticoagulants.
Statistical Analysis
We estimated that 15,200 patients (7600 per group) and 1040 primary events would be necessary to detect a 20 percent relative risk reduction in the primary efficacy end point, with 90 percent power at the two-sided 0.05 significance level in this event-driven trial, assuming an annual event rate of 3.1 percent in the control group and 18 to 42 months of follow-up. The primary efficacy outcome was monitored with use of a Peto–Haybittle type of stopping rule based on the P value of the log-rank test. Two preplanned interim analyses were conducted by a statistician associated with the independent data and safety monitoring board. A two-sided type I error of 0.001 was used at each analysis. A type I error of 0.049 was preserved for the final analysis.
Data were analyzed on an intention-to-treat basis, with the inclusion of all patients according to their randomly assigned treatment group and the inclusion of outcomes occurring from randomization to a common study end date (August 29, 2005). The time to the first occurrence of any event in the composite cluster was used for analysis. Data on patients who did not reach the primary end point by the study end date were censored on the date of the patients' last assessment visit. Death from noncardiovascular causes was treated as a competing event, and follow-up was censored on the date of death.
The primary efficacy of clopidogrel as compared with placebo was assessed with the use of a two-sided log-rank test. The treatment effect as measured by the hazard ratio (the relative risk) and its associated 95 percent confidence interval was estimated with the use of the Cox proportional-hazards model. Cumulative incidence event curves were also calculated. Statistical comparisons of the primary safety-event rates in the two treatment groups were performed with Pearson's chi-square test. No adjustments for multiple comparisons were made. All analyses were performed with SAS software (version 8.0, SAS Institute).
Results
Characteristics of the Patients
A total of 15,603 patients from 32 countries and 768 sites were enrolled between October 1, 2002, and November 14, 2003, in the CHARISMA trial. Of these patients, 7802 were assigned to receive clopidogrel plus aspirin and 7801 were assigned to receive placebo plus aspirin. Treatment was permanently discontinued by 20.4 percent of the patients in the clopidogrel group, as compared with 18.2 percent in the placebo group (P<0.001). A total of 4.8 percent of the patients in the clopidogrel group and 4.9 percent of those in the placebo group discontinued treatment because of an adverse event (P=0.67).
The baseline characteristics of the patients in the trial have been described previously,12 and selected features are listed in Table 2Table 2
Baseline Characteristics.. The median age was 64 years; 29.8 percent of the patients were women. More than three quarters of the participants had established cardiovascular disease, as defined by the enrollment criteria, and most of the remaining patients had multiple atherothrombotic risk factors. On retrospective review of the enrollment information, 166 patients did not fall into either of these categories but were still considered in the broad population analysis.Medications taken by the patients are shown in Table 3Table 3
Concomitant Medications.; these figures indicate the maximal frequency of use of each agent at any time during the trial (with use assessed at baseline and at every follow-up visit). Almost all the patients (aside from those who died or dropped out) took aspirin and the study drug, and 10.2 percent also took open-label clopidogrel. Three quarters took a statin, and more than half took a beta-blocker. Nearly two thirds took an ACE inhibitor, and a quarter took angiotensin II–receptor blocking agents.Efficacy End Points
Follow-up with respect to the primary efficacy end point (the first occurrence of myocardial infarction, stroke, or death from cardiovascular causes) was complete in 99.5 percent of the patients randomly assigned to receive clopidogrel and aspirin and 99.6 percent of those randomly assigned to receive placebo and aspirin. The efficacy results are shown in Table 4Table 4
Composite and Individual Primary and Secondary End Points.. With a median of 28 months of follow-up, the rate of the primary event was 6.8 percent in the clopidogrel group and 7.3 percent in the placebo group (relative risk, 0.93; 95 percent confidence interval, 0.83 to 1.05; P=0.22) (Figure 1AFigure 1Cumulative Incidence of the Primary End Point (Panel A) and of the Secondary End Point (Panel B).). The rate of the principal secondary efficacy end point (the first occurrence of myocardial infarction, stroke, death from cardiovascular causes, or hospitalization for unstable angina, transient ischemic attack, or a revascularization procedure) was 16.7 percent in the clopidogrel group, as compared with 17.9 percent in the placebo group (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.995; P=0.04) (Figure 1B).Safety End Points
The rate of the primary safety end point (severe bleeding according to the GUSTO definition) was 1.7 percent in the clopidogrel group and 1.3 percent in the placebo group (relative risk, 1.25; 95 percent confidence interval, 0.97 to 1.61; P=0.09). The rate of moderate bleeding was 2.1 percent in the clopidogrel group, as compared with 1.3 percent in the placebo group (relative risk, 1.62; 95 percent confidence interval, 1.27 to 2.08; P<0.001). The rate of intracranial hemorrhage was similar in the two treatment groups (Table 4).
There was one documented nonfatal case of thrombotic thrombocytopenic purpura among the clopidogrel-treated patients; this patient died one month later from end-stage chronic obstructive pulmonary disease. No other serious adverse events were reported.
Subgroup Analyses
Several prespecified subgroup analyses classified patients according to their criteria for enrollment (Figure 2Figure 2
Hazard Ratios for Myocardial Infarction (MI), Stroke, or Death from Cardiovascular Causes in Each of the Subgroups Examined.). Patients who were enrolled because they had documented cardiovascular disease were designated “symptomatic,” whereas those who were enrolled because they had multiple atherothrombotic risk factors without documented cardiovascular disease were designated “asymptomatic.” (Some of the latter patients had a reported history of cardiovascular events, including 10.4 percent with a prior myocardial infarction, 5.8 percent with a prior stroke, 5.2 percent with a prior transient ischemic attack, 7.7 percent who had undergone a percutaneous coronary intervention, and 9.8 percent who had undergone coronary-artery bypass grafting, although they did not meet the inclusion criteria for established cardiovascular disease as outlined in Table 1.)Among the 3284 asymptomatic patients, there was a 20 percent relative increase in the rate of primary events with clopidogrel (6.6 percent, vs. 5.5 percent with placebo; P=0.20), whereas among the 12,153 symptomatic patients, there was a marginally significant reduction in the primary end point with clopidogrel (6.9 percent, vs. 7.9 percent with placebo; relative risk, 0.88; 95 percent confidence interval, 0.77 to 0.998; P=0.046). The interaction term for this analysis, when the differential treatment response in asymptomatic and symptomatic patients was examined, was marginally significant (P=0.045).
In the subgroup of asymptomatic patients, there was a significant increase in the rate of death from all causes among the patients assigned to clopidogrel plus aspirin as compared with those assigned to placebo plus aspirin (5.4 percent vs. 3.8 percent, P=0.04) as well as an increase in the rate of death from cardiovascular causes among those assigned to clopidogrel (3.9 percent vs. 2.2 percent, respectively; P=0.01). In contrast, clopidogrel had no significant effect on death from cardiovascular causes in the symptomatic subgroup.
The rates of GUSTO-defined severe bleeding among the asymptomatic patients were 2.0 percent with clopidogrel and 1.2 percent with placebo (P=0.07); the corresponding rates among the symptomatic patients were 1.6 percent and 1.4 percent (P=0.39). Although both these differences favored the placebo group, neither was significant. The rates of GUSTO-defined moderate bleeding among asymptomatic patients were increased (2.2 percent with clopidogrel and 1.4 percent with placebo, P=0.08), as were the rates of moderate bleeding among symptomatic patients (2.1 percent and 1.3 percent, respectively; P<0.001). Again, both differences favored the placebo group, but this difference was significant only among the symptomatic patients.
Discussion
In this trial of patients with established atherothrombotic disease or at high risk for such disease, there was no significant benefit associated with clopidogrel plus aspirin as compared with placebo plus aspirin in reducing the incidence of the primary end point of myocardial infarction, stroke, or death from cardiovascular causes. There was a moderate, though significant, benefit in reducing the secondary composite end point of myocardial infarction, stroke, death from cardiovascular causes, or hospitalization for unstable angina, transient ischemic attack, or revascularization.
The rate of severe bleeding was not significantly greater with clopidogrel than with placebo, but a trend prompting concern was noted, and clopidogrel was associated with a significant increase in the rate of moderate bleeding. A total of 94 ischemic (secondary) end points were prevented with clopidogrel, at a cost of 93 moderate or severe bleeding events.
The patients in our trial received evidence-based pharmacologic treatment, with frequent use of concomitant statins, ACE inhibitors, and other background medical therapy. The incidence of the primary end point with such therapy, as predicted, was approximately 3 percent per year.
In the original, large-scale Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial,13 clopidogrel alone was found to be superior to aspirin alone in reducing the risk of ischemic stroke, myocardial infarction, or death from vascular causes. However, there was debate as to whether P2Y12-receptor blockade provided uniform benefit. Since CAPRIE, four large clinical trials have added to the body of evidence that supports the use of dual antiplatelet therapy in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention.6-9 CHARISMA represented the logical next step of evaluation of the potential role of this approach in a broad population of patients with established vascular disease or multiple cardiovascular risk factors.
A subgroup analysis suggested that clopidogrel was beneficial with respect to the primary efficacy end point in patients who were classified as symptomatic for the purposes of the trial (i.e., who were enrolled because of a documented history of established vascular disease). However, the P value for this association and the P value for the interaction between enrollment status and therapy were only marginally significant, suggesting that this observation should be interpreted with caution, especially since this subgroup analysis was only one of several such analyses performed. Furthermore, the risk of moderate or severe bleeding in symptomatic patients was greater with clopidogrel than with placebo, although there was no significant increase in intracranial or fatal bleeding. Finally, as a practical matter, it is unclear how such a classification could be implemented clinically, since some patients in the asymptomatic subgroup actually had a history of symptoms or cardiovascular events. The issue of whether dual antiplatelet therapy is beneficial in more specific subgroups of the population of patients with atherothrombotic disease or risk will require further study.
On the other hand, the risk associated with dual antiplatelet therapy in the asymptomatic group was not anticipated. The excess fatalities in this subgroup and the heightened risk of bleeding complications suggest that we should be cautious about too quickly dismissing this unexpected finding as the play of chance. It is possible that established vascular disease represents a crude proxy for hyperactive platelets. If this concept is accepted, dual antiplatelet therapy would be anticipated to be associated with greater efficacy and a lower rate of bleeding in the subgroup of symptomatic patients. However, reduced basal platelet activity in asymptomatic patients would be expected to be a liability, increasing the risk of bleeding complications, including possible hemorrhage into an arterial plaque. Whatever the explanation, it appears that until proven otherwise, clinicians should avoid dual antiplatelet therapy in patients without established vascular disease.
Recent studies of the genomics of myocardial infarction and atherosclerosis have revealed a marked difference among persons in the biologic basis of disease susceptibility. Whereas multiple genes have been demonstrated to confer susceptibility to heart attack, little has been reported on the molecular determinants of atherosclerosis in humans.14 Atherosclerosis is far more common than are vascular events such as sudden death, heart attack, and stroke, which occur in a relatively small subgroup of patients. One hypothesis that could be consistent with a benefit of dual antiplatelet therapy in symptomatic patients (those with established vascular disease) is that this group has already shown a predisposition to arterial plaque rupture, fissure, or erosion. That dual antiplatelet therapy is best used in patients who are most liable to have such arterial injury appears to be a worthy hypothesis for prospective evaluation.
In summary, the combination of clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes among patients with stable cardiovascular disease or multiple cardiovascular risk factors. Furthermore, the risk of moderate-to-severe bleeding was increased. Our findings do not support the use of dual antiplatelet therapy across the broad population tested. There was a potential benefit in symptomatic patients (those with established vascular disease); this finding requires further study. Data on mortality rates suggest that dual antiplatelet therapy should not be used in patients without a history of established vascular disease.
Sponsored and funded by Sanofi-Aventis and Bristol-Myers Squibb. Dr. Topol is supported by grants (P50 HL077101 and HL081011) from the National Institutes of Health.
Dr. Bhatt reports having received consulting fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Millennium, Sanofi-Aventis, Schering-Plough, and the Medicines Company; lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, and the Medicines Company; and having provided expert testimony regarding clopidogrel (the compensation was donated to a nonprofit organization). Dr. Fox reports having received consulting fees from Sanofi-Aventis; lecture fees from Sanofi-Aventis and Bristol-Myers Squibb; and grant support from Sanofi-Aventis. Dr. Hacke reports having received consulting and lecture fees from Sanofi-Aventis and Bristol-Myers Squibb. Dr. Berger reports having received consulting and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Johnson & Johnson, Genentech, Guilford, Arginox, Schering-Plough, and Boston Scientific, and is the medical director and owns equity in Lumen. Dr. Black reports having received consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, Merck, Pfizer, Novartis, and Myogen and lecture fees from Sanofi-Aventis, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, and Novartis. Dr. Boden reports having received consulting fees and lecture fees from Sanofi-Aventis, Bristol-Myers Squibb, KOS Pharmaceuticals, PDL BioPharma, and CV Therapeutics. Dr. Cacoub reports having received consulting fees from Servier, Schering-Plough, Roche, and Chiesi and lecture fees from Sanofi-Aventis, Bristol-Myers Squibb, Servier, Schering-Plough, Abbott, and Chiesi. Dr. Cohen reports having received consulting fees from Hoffmann–La Roche, Eli Lilly Canada, Oryx Pharmaceuticals, and GlaxoSmithKline Canada and lecture fees from Sanofi-Aventis, Oryx Pharmaceuticals, Eli Lilly Canada, and Key Schering. Dr. Creager reports having received consulting fees and grant support from the Sanofi-Aventis/Bristol-Myers Squibb partnership and lecture fees from Sanofi-Aventis/Bristol-Myers Squibb. Dr. Easton reports having received consulting fees from Sanofi-Aventis and Bristol-Myers Squibb. Dr. Flather reports having received consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, GlaxoSmithKline, and Boehringer Ingelheim; lecture fees from Sanofi-Aventis, Bristol-Myers Squibb, GlaxoSmithKline, and Menarini; and grant support from Sanofi-Aventis, Bristol-Myers Squibb, GlaxoSmithKline, and Novartis. Dr. Haffner reports having received consulting and lecture fees from Sanofi-Aventis. Dr. Hamm reports having received consulting and lecture fees from Sanofi-Aventis. Dr. Hankey reports having received consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, Bayer, and Boehringer Ingelheim and lecture fees from Sanofi-Aventis, Bristol-Myers Squibb, Bayer, and Boehringer Ingelheim. Dr. Johnston reports having received a grant from Johnson & Johnson. Dr. Mas reports having received consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, and Servier and lecture fees from Sanofi-Aventis and Bristol-Myers Squibb. Dr. Montalescot reports having received consulting and lecture fees from Sanofi-Aventis and Bristol-Myers Squibb. Dr. Pearson reports having received consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, Bayer, Forbes Medi-Tech, and Merck and lecture fees from Bristol-Myers Squibb, Abbott, AstraZeneca, Bayer, KOS Pharmaceuticals, Merck, Pfizer, and Merck/Schering-Plough. Dr. Steg reports having received consulting fees from Sanofi-Aventis, AstraZeneca, Takeda, and GlaxoSmithKline and lecture fees from Sanofi-Aventis, Bristol-Myers Squibb, AstraZeneca, Servier, Merck, Novartis, Sankyo, Boehringer Ingelheim, Pfizer, and Nycomed. Dr. Steinhubl reports having received consulting fees from Sanofi-Aventis, AstraZeneca, Eli Lilly, and the Medicines Company. Dr. Weber reports having received lecture fees from Sanofi-Aventis and Bristol-Myers Squibb. Dr. Topol reports having served as a consultant to and having received lecture fees from Sanofi-Aventis and Bristol-Myers Squibb before 2005. No other potential conflict of interest relevant to this article was reported.
This article was published at www.nejm.org on March 12, 2006.
We are indebted to Bernard Job, M.D., and Christophe Gaudin, M.D., from Sanofi-Aventis and Mel Blumenthal, M.D., and Ravi Saini, M.D., from Bristol-Myers Squibb for their efforts on behalf of the CHARISMA trial, as well as to the 15,603 patients in 32 countries who participated in the trial.
Source Information
From Cleveland Clinic, Cleveland (D.L.B., D.M.B., L.F.-R., J.B.); University and Royal Infirmary of Edinburgh, Edinburgh (K.A.A.F.); University of Heidelberg, Heidelberg, Germany (W.H.); Duke University, Durham, N.C. (P.B.B.); Rush Medical College, Chicago (H.R.B.); Hartford Hospital, Hartford, Conn. (W.E.B.); Hôpital Pitié-Salpêtrière (P.C.), Sainte-Anne Hospital (J.-L.M.), Institut de Cardiologie–CHU Pitié-Salpêtrière (G.M.), and Hopital Bichat (P.G.S.) — all in Paris; Sunnybrook and Women's College Health Science Centre, Toronto (E.A.C.); Brigham and Women's Hospital and Harvard Medical School, Boston (M.A.C.); Rhode Island Hospital and Brown University, Providence (J.D.E.); Royal Brompton Hospital, London (M.D.F.); University of Texas Health Science Center at San Antonio, San Antonio (S.M.H.); Kerckhoff-Klinik Center, Bad Nauheim, Germany (C.W.H.); Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth (G.J.H.); University of California, San Francisco, San Francisco (S.C.J.); Gleneagles Medical Centre, Singapore (K.-H.M.); University of Rochester School of Medicine, Rochester, N.Y. (T.A.P.); University of Kentucky, Lexington (S.R.S.); SUNY Downstate Medical Center, Brooklyn, N.Y. (M.A.W.); and Case Western Reserve University, Cleveland (E.J.T.).
Address reprint requests to Dr. Topol at the Department of Genetics, Case Western Reserve University, BRB 724, 10900 Euclid Ave., Cleveland, OH 44106-4955, or at eric.topol@case.edu.
The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) committees, national coordinators, and investigators are listed in the Appendix.
Appendix
The CHARISMA committees, national coordinators, and investigators are as follows: Executive committee: E.J. Topol (chair), K.A.A. Fox (cochair), W. Hacke (cochair), D.L. Bhatt (principal investigator), P.B. Berger, H.R. Black, W.E. Boden, P. Cacoub, E.A Cohen, M.A. Creager, J.D. Easton, M.D. Flather, S.M. Haffner, C.W. Hamm, G.J. Hankey, S. Claiborne Johnston, K.-H. Mak, J.-L. Mas, G. Montalescot, T.A. Pearson, P.G. Steg, S.R. Steinhubl, M.A. Weber; Independent data and safety monitoring board: R.L. Frye (chair), P. Amarenco, L.M. Brass, M. Buyse, L.S. Cohen, D.L. DeMets, V. Fuster, R.G. Hart, J.R Marler, C. McCarthy, A. Schömig; Clinical events committee: A.M. Lincoff (chair), S.J. Brener (cardiology), C.A. Sila (neurology), A. Albuquerque, G. Aroutiounov, D. Artemiev, B.G. Atkeson, T. Bartel, D.C.G. Basart, A. Bastos Lima, G. Belli, A.L. Bordalo e Sá, X. Bosch, G. Boysen, E.W.A. Busch, A. Cavallini, A. Chamorro Sánchez, J.H. Chiu, T. Dahl, E. Danielsson, R.B. Fathi, P. Grande, K. Groundstroem, M. Hamon, M. Haude, C. Held, B. Hesse, M.A. Hook, J.C. Hostetter, J.C. Huang, R.C. Jones, A. Kamińska, K. Karlócai, S. Marcheselli, J. Martí-Fàbregas, R. Mikulik, J.P. Neau, Y. Nişanci, H.J. Nordal, T. Okay, G. Opala, I.A. Orlova, V. Parfenov, T.J. Pasierski, G. Permanyer-Miralda, A. Plomaritoglou, P. Pruszczyk, G. Rasmanis, R.O. Roine, A. Rónaszéki, M.L. Rossi, K. Sas, R.W. Shields, J. Sitar, B. Srichai, J. Stam, P.J. Sweeney, M.S. Syvänne, D. Tschopp, K. Urbánek, M. Vavuranakis, L. Vécsei, M.V. Baptista, P. Vojtíšek, F. Woimant, and F. J. Zidar; National coordinators: Argentina — S.F. Ameriso, F.A. Cura; Australia — P. Aylward, G.J. Hankey; Belgium — B.J. Boland; Brazil — A. Amato, V. De Paola; Canada — E.A. Cohen, A. Roussin, P. Teal; Czech Republic — E. Ehler; Denmark — H. Sillesen; Finland — M.S. Nieminen; France — P.G. Steg; Germany and Austria — U. Hoffmann, F.-J. Neumann; Greece — A.P. Dimas; Hungary — T. Forster; Italy — D. Ardissino; Mexico — R. Alvarado; the Netherlands — H.R. Büller; Norway — B. Indredavik; Poland — Z.A. Gaciong; Portugal — J. Morais; Russia — V. Mareev; Spain — A. Betriu, L.M. Ruilope; South Africa — A.J. Dalby; Sweden — J.B. Östergren; Switzerland — T.F. Luscher; Turkey — H. Kultursay; United Kingdom — M.D. Flather, K.A.A. Fox; and United States — W.E. Boden, J.D. Easton, S.M. Haffner, T.A. Pearson, S.R. Steinhubl; Investigators: Argentina — A. Alvarisqueta, S. Ameriso, L. Maria Amuchastegui, A. Caccavo, I. Casas Parera, S. Chekherdemian, F. Cura, M.M. Esnaola y Rojas, M. Fernandez Pardal, J. Ferrari, H. Fideleff, E. Hasbani, R. La Mura, J.L. Presta, R. Rey, R. Rey, R. Rivas, D.G. Starosiliz, A. Villamil, J. Waitman, and P. Zaefferer; Australia — J. Amerena, C. Bladin, D. Chew, D. Crimmins, D. Cross, S. Davis, T. Davis, G. Donnan, R. Fitridge, D. Freilich, H. Gibbs, J. Graham, A. Hill, J. Horowitz, D. Hunt, N. Ingham, J. Karrasch, I. Meredith, R. Moses, P. Phillips, J. Rankin, S. Read, D. Rees, S. Roger, J. Sampson, R. Schwartz, P. Walker, G. Watts, A. Whelan, and R. Whitbourn; Austria — B. Eber, H. Niessner, E. Pilger, R. Schmidt, T. Wascher, and J. Willeit; Belgium — S. Blecic, B.J. Boland, J. Boland, G. Boxho, P.P. De Deyn, J. Duchateau, J. Ducobu, G.R. Heyndrickx, F. Sanchez-Ruiz, A. Scheen, V. Thijs, W. Van Mieghem, and E. Verjans; Brazil — Â.A.V. de Paola, A. Francischetti, E. Francischetti, F.A. Frota Bezerra, R. Gagliardi, A. Massaro, Y. Nagato, K. Nakiri, S. Rassi, C. Scherr, J.A. Sgarbi, J. Soares Felício, and H. Suplicy; Canada — R. Arts, P. Auger, C.E.H. Baer, G. Bailey, P. Bailey, M. Beaudry, J. Bédard, L. Berger, J.D. Berlingieri, R.K. Bhargava, P. Bogaty, D. Bruckschwaiger, M.H. Cameron, M. Chilvers, S. Connolly, C. Constance, H.S. Conter, R. Cote, J. Cusson, H. Desai, L. Desjardins, R.A. Dlin, A. Durocher, C. Fortin, Y.-D. Gagnon, A. Glanz, S.G. Goodman, D. Gossard, M.K. Gupta, V. Hachinski, D. Hambly, R.D. Hamilton, B. Hejdankova, J. Hii, W. Hughes, W.K.K. Hui, J. Janzen, D. Johnston, C. Joyner, W.P. Klinke, S. Kouz, P.L Allier, R. Labbé, S.S.Y. Lam, D.A. Landry, C. Laroche, B.J. Lawlor, J.H.F. Lenis, P. Ma, A. Mackey, D.R. Marr, J. Milton, J. Minuk, M.-J. Miron, K.K.A. Misik, G. Moddel, T. Monchesky, P. Nault, W.F. O'Mahony, A. Panju, A. Penn, P. Perron, S. Phillips, K. Pistawka, B.R. Ramjattan, J.A. Ricci, J. Rodés, D. Sahlas, D. Selchen, M. Sharma, A. Shuaib, D. Spence, D.C. Steeves, D. Studney, J. Sullivan, B.A. Sussex, P. Teal, J. Teitelbaum, H.D. Tildesley, S.J. Tishler, A.G.G. Turpie, C. Voll, J.W. Warnica, M.A. Weigel, T. Winder, M. Winger, V.C. Woo, P. Wozniak, J.-F. Yale, L.C.H. Yao, G. Zimakas, and R. Zimmermann; Chile — R. Corbalan, P. Lavados, and J. Yovanovich; Czech Republic — M. Bar, M. Branny, J. Charvat, E. Ehler, B. Filipensky, M. Filipova, J. Smid, J. Spac, J. Spinar, F. Stanek, and E. Zidkova; Denmark — M. Carstensen, S.E. Husted, H. Kraemmer-Nielsen, and K. Lindvig; Finland — J. Airaksinen, M.S. Nieminen, and J. Sivenius; France — N. Abenhaim, B. Agraou, M. Bismuth, H. Boccalon, M. Bourgoin, M.-G. Bousser, P. Carpentier, I. Cibois-Honnorat, C. Conri, B.D. Hautefeuille, P. Dambrine, M. David, H. Decousus, B. Devulder, J.-L. Dubois-Rande, E. Ferrari, R. Fonteny, L. Fuchs, M. Giroud, J.-L. Guilmot, M. Krempf, M.-H. Mahagne, J.-L. Mas, A. Medvedowsky, G. Montalescot, T. Moulin, J.-F. Pinel, J. Puel, I. Quere, G. Rodier, T. Rosolacci, F. Rouanet, D. Saillard, G. Steg, D. Stephan, C. Tribouilloy, J.-Y. Vogel, and Y. Samson; Germany — C. Baran, J. Berrouschot, O. Busse, M. Dichgans, H.-C. Diener, H.-G. Fritz, M. Goertler, B. Griewing, T. Haak, R. Haberl, C. Hamm, J. Hein, T. Heitzer, M. Hennerici, U. Hoffmann, T. Horacek, G. Klausmann, H. Lawall, G. Mahla, H. Mauersberger, G. Meinhardt, A. Müller-Jensen, T. Münzel, P. Nawroth, F.-J. Neumann, H. Ochs, P. Ringleb, H. Samer, D. Sander, P. Scheffler, K.-L. Schulte, S. Silber, U. Speier, K. Stangl, E. Stark, C. Tiefenbacher, P. von Bilderling, M. Weisbach, and J. Wunderlich; Greece — A. Dimas, M. Elisaf, D. Karamitsos, A. Melidonis, E. Pagkalos, A. Polydorou, C. Saopoulos, K. Vemmos, and G. Ziakas; Hong Kong — J. Chan, W. Kwong Chan, W.-H. Chen, R. Cheung, S.-K. Li, K. Tan, K. Sing, L. Wong, and K.-S. Woo; Hungary — G. Acsády, K. Cseh, L. Csiba, M. Csornai, T. Forster, C. Kerekes, L. Kollár, V. Kristóf, Z. László, A. Murányi, J. Sebestyén, and M. Sereg; Italy — E. Agabiti Rosei, P. Bassi, D. Cucinotta, E. Degli Esposti, F. Federico, S. Forconi, N. Glorioso, P. Gresele, D. Guidetti, E. Mannarino, F. Masini, G. Micieli, A. Morganti, R. Pasquali, P. Carlo Rossi, L. Saccà, M.L. Sacchetti, A. Spissu, P. Terrosu, and F. Violi; Malaysia — N.A. bin Kamaruddin, S. Pheng Chan, and K.-S. Tan; Mexico — C. Aguilar, R. Alvarado, A. Arauz, C.-G. Ascanio, N.-S. Barroso, L.-F. Flota, S. Hernandez, R. Herrera, J.-L. Leyva, E. Meaney, A. Miranda, E. Morales, B. Ramirez, A. Ranero, M.A. Rivera, J.L. Ruiz, C.-J. Sanchez, and J.-A. Tamez; Norway — D. Atar, B. Indredavik, and P.A. Sirnes; Poland — P. Andziak, F. Brakowiecki, A. Cencora, M. Cholewa, Z. Gaciong, P. Gutowski, J. Huczynski, K. Janik, A. Jawien, G. Kania, D. Kleczkowski, J. Kotowicz, W. Krasowski, M. Kruk, A. Kuczynska-Zardzewialy, H. Kwiecinski, J. Lopatynski, M. Muszynska-Polaszewska, M. Piepiorka, K. Pilarska, R. Podemski, J. Rudzinski, A. Rynkiewicz, M. Strzelecka-Gorzynska, A. Szczudlik, M. Szpajer, B. Wierusz-Wysocka, D. Wojciechowski, B. Wyrzykowski, P. Zaleski, B. Zalska, and K. Ziaja; Portugal — L. Cunha, D. Ferreira, J. Ferro, L. Gardete Correia, P. Marques da Silva, J. Morais, L. Mota Capitão, J. Puig, and V. Salgado; Russia — J. Belousov, N. Gratsiansky, V. Mareev, A. Sinopalnikov, A. Skoromets, V. Skvortsova, L. Stratchounsky, and Z. Suslina; Singapore — A. Auchus, H.-M. Chang, K. Hou Mak, N.V. Ramani, and J. Chin Tay; South Africa — P. Blomerus, A. Bryer, L. Burgess, A.J. Dalby, L. Distiller, I.O. Ebrahim, G.C. Ellis, M.R. Essop, J. King, E. Lloyd, R. Moore, R. Sommers, L. Steingo, and M. Van Niekerk; Spain — J.M. Aguilera, J. Alvarez-Sabin, M. Cairols, C. Calvo, J. Castillo, A. Coca, A. Davalos, F. De Alvaro, A. Flores, J. García Puig, A. Gil-Peralta, P. Gomez, M. Heras, C. Macaya, A.M. Hidalgo, J. Matías-Guiu, E. Mostacero, R. Romero, E. Ros Die, L.M. Ruilope, J. Serena, N. Vila, and J. Vivancos; Sweden — L. Bokemark, B. Cederin, S. Karacagil, J. Östergren, T. Strand, and R. Undén-Göransson; Switzerland — I. Baumgartner, J.H. Beer, J. Bogousslavsky, H. Bounameaux, B. Caduff, A. Cerny, A. Gallino, T. Luescher, P. Lyrer, and A. Pagnamenta; Taiwan — J.-J. Cheng, H.-T. Chou, H.-W. Huang, and S.-J. Ryu; the Netherlands — D.H. Biesma, D.P.M. Brandjes, H.R. Büller, F.R. den Hartog, D.W.J. Dippel, M.H.H. Kramer, J.W.M. Lenders, H.R. Michels, M.G. Niemeijer, P.R. Nierop, J.U.R. Niewold, M.G.C. Pieterse, E.A.C.M. Sanders, P.J.H. Smak Gregoor, J. Teijink, R.P.T. Troquay, and B. van Vlies; Turkey — S. Balkan, M. Bayazit, K. Gol, B. Ince, H. Kultursay, E. Kumral, K. Kutluk, and H. Tuzun; United Kingdom—J. Adgey, P. Bath, J. Belch, M.J. Brack, L.A. Corr, R. Curless, R. Donnelly, J.A. Dormandy, P. Durrington, S.J. Ellis, M.D. Flather, K.A.A. Fox, D. Jenkinson, K.R. Lees, R.S. MacWalter, D. McEneaney, A. Mehrzad, K. Muir, C. Murphy, J.A. Purvis, T. Robinson, H.G.M. Shetty, D. Sprigings, G. Stansby, and G.S. Venables; United States— A. Abou-Zamzam, H. Adams, F.V. Aguirre, B. Ahmad, J.R. Allison III, A. Almahameed, I. Altafullah, J. Anderson, R. Arakaki, G. Arnold, R. Avva, A. Axelrod, J.M. Bacharach, D. Banish, A. Bank, G.G. Banks, S. Bansal, C. Bayron, K.J. Becker, L. Becnel, A. Belber, J.R. Belden, D. Bernstein, H.S. Bhatia, J. Bittrick, W.E. Boden, K.K. Bordenave, T. Bowers, A.J. Bradley, J.R. Brady, S. Brady, J. Brandes, A. Brateanu, D. Brautigam, D. Brill, J. Brillman, R.E. Broker, D. Brotman, C. Brown, T.E. Bruya, J. Kern Buckner, D. Buth, T. Byer, L. Cannon, R. Capodilupo, J.M. Cappleman, E.L. Chaikof, J. Chambers, H. Chandna, Y. Pragada Chandrashekhar, C. Chen, T. Chippendale, S. Chokshi, P. Clagett, K. Cohen, M. Collins, A. Comerota, J.R. Cook, J. Corbelli, M.A. Creager, F.H. Cucher, F.E. Cummins, B. Dandapani, K. Dave, G.E. DeGent, M. DeGregorio, D.P. DeHart, J. DeLeon, T. Devlin, B. DeVries, M. Drehobl, M.N. Drossner, M. Dryjski, D. Dulli, D. Eisenberg, W.T. Ellison, S. Erlemeier, W. Felten, W. Felton, P.E. Fenster, H. Fields, T. Fischel, A. Furlan, M. Gandhi, R. Gaona, S. Gazda, J. Gelormini, A. George, J. George, W. George, S. Gill, J.M. Glass, M.C. Goldberg, S. Goldman, J. Goldstein, M.A. Goodman, B.P. Grayum, J. Greenberg, G. Grewal, J. Griffin, R. Griffin, Jr., E. Gross-Sawicka, D. Gupta, S. Gupta, L. Gutnik, B. Haake, J.L. Haist, J. Hanna, J. Harris, B. Harrison, M.V. Hart, R. Hendley, T. Henry, P. Hermany, C. Herrera, J. Hoch, J. Hollander, V.N. Howard, T. Huber, R. Hull, R.J. Hye, B. Iteld, S.A. Jackson, B. Jacobs, L. Jacobs, C. Jenkins, C. Johnson, L. Toyono Jong, K. Kaplan, R.A. Kaplan, S. Katz, C.J. Kavinsky, R. Kelley, B. Kerzner, E.J. Klein, G. Koshkarian, M. Kozak, V. Krisciunas, K. Kutoloski, N. Lakkis, M. Lasala, J.R. LaSalle, B. Latthe, P. Lee-Kwen, K.G. Lehmann, D. Leifer, J. LeLevier, D. Lender, K. Levin, M. Levine, P. Lewis, R. Libman, T. Little, G. Locke, R. Loeffler, D. Lorch, T.J. Lowenkopf, M. Lurie, F. Maggiacomo, J.D. Martin, B. Massie, E.K. Massin, T.G. Mattio, W. McGuinn, R.J. Meckler, M. Meredith, J.H. Mersey, A. Miller, J. Miller, L. Miller, P. Misch, J. Modrall, A.D. Mooradian, J.T. Morelli, A. Nafziger, S.D. Nash, K. Ng, A. Niederman, J.P. O'Bryan, P. Ogden, J. Miller Oppy, J.D. Orr, F. Ovalle, P. Overlie, C.K. Ozaki, T. Pacheco, B. Peart, C. Perkins, F. Pettyjohn, I. Pines, J. Pita, T. Poling, A.R. Pollack, S. Pollock, G.L. Post, J.B. Powers, R. Prashad, G. Raad, M. Raikhel, M. Rajachandran, R. Reichwein, M. Rendell, P.S. Reynolds, M. Rich, T. Richardson, K. Rictor, M.E. Ring, M. Rocco, B. Rogers, E.M. Roth, W.M. Ryan, J. Salmon, R. Sanchez, J.A. Schecter, K.C.J. Scherbarth, J. Schrenker, U. Schubart, A. Schussheim, J. Seaworth, P. Seigel, S. Shah, N. Shammas, W.S. Sheldon, L. Shelhamer, D. Sherman, R. Shey, T.L. Shook, R. Shor, R. Sievert, S. Silliman, B. Silver, H. Simon, W. Slater, G. Sloan, J. Smith III, W.B. Smith, B. Snyder, D. Som, C. Sotolongo, A. Spaedy, D. Spriggs, S. Steen, S. Stenstrom, L.D. Stonesifer, D. Subich, D.P. Suresh, R. Tamayo, W.A. Tan, G. Tefera, U. Thadani, R. Tidman, A. Tilkian, M.J. Tonkon, A. Turel, D. VanSickle, C. Vernon, W. Voyles, J. Walder, M. Warren, K. Weber, K. Weeks, R.J. Weiss, N. Weiss, J.H. Whitaker, D. Wolinsky, W. Wu, J. Yadav, and G.D. Yeoman.
- References
References
1
Ruggeri ZM . Platelets in atherothrombosis. Nat Med 2002;8:1227-1234
CrossRef | Web of Science | Medline2
Fuster V ,Moreno PR ,Fayad ZA ,Corti R ,Badimon JJ . Atherothrombosis and high-risk plaque. I. Evolving concepts. J Am Coll Cardiol 2005;46:937-954
CrossRef | Web of Science | Medline3
Lopez AD ,Murray CC . The global burden of disease, 1990-2020. Nat Med 1998;4:1241-1243
CrossRef | Web of Science | Medline4
Bhatt DL ,Steg PG ,Ohman EM , et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189
CrossRef | Web of Science | Medline5
Antithrombotic Trialists' Collaboration
CrossRef | Web of Science6
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Full Text | Web of Science | Medline7
Chen ZM ,Jiang LX ,Chen YP , et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-1621
CrossRef | Web of Science | Medline8
Steinhubl SR ,Berger PB ,Mann JT III , et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420[Erratum, JAMA 2003;289:987.]
CrossRef | Web of Science | Medline9
Sabatine MS ,Cannon CP ,Gibson CM , et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189
Full Text | Web of Science | Medline10
Bhatt DL ,Topol EJ . Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004;148:263-268
CrossRef | Web of Science | Medline11
The GUSTO Investigators
Full Text | Web of Science | Medline12
Bhatt DL, Fox KA, Hacke W, et al. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2005;150(3):401.e1–401.e7. (Accessed March 24, 2006, at http://www.ahjonline.com/article/PIIS000287030500284X/fulltext#abstract.)
13
CAPRIE Steering Committee
CrossRef | Web of Science | Medline14
Topol EJ . Simon Dack Lecture: the genomic basis of myocardial infarction. J Am Coll Cardiol 2005;46:1456-1465
CrossRef | Web of Science | Medline
- Citing Articles (651)
Citing Articles
1
Emile Calenda, Laure Lamothe, Olivier Genevois, Annie Cardon, Marc Muraine. (2012) Peribulbar block in patients scheduled for eye procedures and treated with clopidogrel. Journal of Anesthesia
CrossRef2
Mark Fisher, Vitaly Vasilevko, David H. Cribbs. (2012) Mixed Cerebrovascular Disease and the Future of Stroke Prevention. Translational Stroke Research
CrossRef3
, J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, M. Verschuren, C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim, M. Fisher, G. Germano, R. Hobbs, A. Hoes, S. Karadeniz, A. Mezzani, E. Prescott, L. Ryden, M. Scherer, M. Syvanne, W. J. M. Scholte Op Reimer, C. Vrints, D. Wood, J. L. Zamorano, F. Zannad, , M. T. Cooney, , J. Bax, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, , C. Funck-Brentano, P. A. Sirnes, V. Aboyans, E. A. Ezquerra, C. Baigent, C. Brotons, G. Burell, A. Ceriello, J. De Sutter, J. Deckers, S. Del Prato, H.-C. Diener, D. Fitzsimons, Z. Fras, R. Hambrecht, P. Jankowski, U. Keil, M. Kirby, M. L. Larsen, G. Mancia, A. J. Manolis, J. McMurray, A. Pajak, A. Parkhomenko, L. Rallidis, F. Rigo, E. Rocha, L. M. Ruilope, E. van der Velde, D. Vanuzzo, M. Viigimaa, M. Volpe, O. Wiklund, C. Wolpert. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal
CrossRef4
Hannah Lee, Justin R. Hamilton. (2012) Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease. Pharmacology & Therapeutics 134:2, 246-259
CrossRef5
Baotao Huang, Yan Huang, Yulin Li, Hongmei Yao, Xianchao Jing, He Huang, Jing Li. (2012) Adverse Cardiovascular Effects of Concomitant Use of Proton Pump Inhibitors and Clopidogrel in Patients with Coronary Artery Disease: A Systematic Review and Meta-Analysis. Archives of Medical Research
CrossRef6
Valeria Caso, Paola Santalucia, Monica Acciarresi, Francesca Romana Pezzella, Maurizio Paciaroni. (2012) Antiplatelet treatment in primary and secondary stroke prevention in women. European Journal of Internal Medicine
CrossRef7
Christoph Varenhorst, Stefan James. (2012) Which Antiplatelet Agent for Whom? Which Patient Populations Benefit Most from Novel Antiplatelet Agents (Ticagrelor, Prasugrel)?. Current Cardiology Reports
CrossRef8
Paul Statkevich, Teddy Kosoglou, Richard A. Preston, Bharath Kumar, Fengjuan Xuan, Craig Trusley, James E. Schiller, Ronald B. Langdon, David L. Cutler. (2012) Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. European Journal of Clinical Pharmacology
CrossRef9
Morrow, David A., Braunwald, Eugene, Bonaca, Marc P., Ameriso, Sebastian F., Dalby, Anthony J., Fish, Mary Polly, Fox, Keith A.A., Lipka, Leslie J., Liu, Xuan, Nicolau, José Carlos, Ophuis, A.J. Oude, Paolasso, Ernesto, Scirica, Benjamin M., Spinar, Jindrich, Theroux, Pierre, Wiviott, Stephen D., Strony, John, Murphy, Sabina A., . (2012) Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine 366:15, 1404-1413
Full Text10
Peter Kan, Maxim Mokin, Travis M. Dumont, Kenneth V. Snyder, Adnan H. Siddiqui, Elad I. Levy, L. Nelson Hopkins. (2012) Cervical Carotid Artery Stenosis: Latest Update on Diagnosis and Management. Current Problems in Cardiology 37:4, 127-169
CrossRef11
Michael C Wallace, Jamie Rankin, Geoffrey M Forbes. (2012) Acute gastrointestinal bleeding after percutaneous coronary intervention. Expert Review of Gastroenterology & Hepatology 6:2, 211-221
CrossRef12
Freek W.A. Verheugt. (2012) Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: Necessary or too hazardous?. American Heart Journal 163:4, 531-534
CrossRef13
Matthew S. West, Ethan U. Cumbler. (2012) Acute Ischemic Stroke. Hospital Medicine Clinics 1:2, e223-e237
CrossRef14
D. L. Bhatt, G. Pare, J. W. Eikelboom, K. L. Simonsen, E. S. Emison, K. A. A. Fox, P. G. Steg, G. Montalescot, N. Bhakta, W. Hacke, M. D. Flather, K.-H. Mak, P. Cacoub, M. A. Creager, P. B. Berger, S. R. Steinhubl, G. Murugesan, S. R. Mehta, K. Kottke-Marchant, A. M. Lincoff, E. J. Topol, . (2012) The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European Heart Journal
CrossRef15
Ayeesha K Kamal, Shaista A Siddiqi, Imama Naqvi, Maria Khan, Farzin Majeed, Bilal Ahmed, Ayeesha K Kamal. 2012. Multiple versus one or more antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. .
CrossRef16
Bruce A. Warden, Alana M. Willman, Craig D. Williams. (2012) Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nature Reviews Neurology
CrossRef17
Teddy Kosoglou, Walter K. Kraft, Bharath Kumar, Paul Statkevich, Fengjuan Xuan, Lei Ma, Lisa K. Jennings, James E. Schiller, Ronald B. Langdon, David L. Cutler. (2012) Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. European Journal of Clinical Pharmacology
CrossRef18
Dan Clair, Samir Shah, John Weber. (2012) Current State of Diagnosis and Management of Critical Limb Ischemia. Current Cardiology Reports
CrossRef19
Linnea M. Baudhuin. 2012. Pharmacogenomics of Cardiovascular Drugs. , 98-126.
CrossRef20
Yong-Jun Wang, Su-Ming Zhang, Liqun Zhang, Chun-Xue Wang. (2012) Chinese Guidelines for the Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack 2010. CNS Neuroscience & Therapeutics 18:2, 93-101
CrossRef21
Giovanni Davì, Natale Vazzana, Simona Sestili. (2012) Variability in the response to antiplatelet treatment in diabetes mellitus. Prostaglandins & Other Lipid Mediators
CrossRef22
Michel Tendera, Victor Aboyans, Marie-Louise Bartelink, Iris Baumgartner, Denis Clément, Jean-Philippe Collet, Alberto Cremonesi, Marco De Carlo, Raimund Erbel, F. Gerry R. Fowkes, Magda Heras, Serge Kownator, Erich Minar, Jan Ostergren, Don Poldermans, Vincent Riambau, Marco Roffi, Joachim Röther, Horst Sievert, Marc van Sambeek, Thomas Zeller. (2012) Guía de práctica clíníca de la ESC sobre diagnóstico y tratamiento de las enfermedades arteriales periféricas. Revista Española de Cardiología 65:2, 172.e1-172.e57
CrossRef23
Maxim Mokin, Elad I. Levy. (2012) What Is the Best Medical Treatment for Symptomatic Intracranial Stenosis?. World Neurosurgery 77:2, 235-237
CrossRef24
Robert Janknegt, Lex Ruiters, Hugo ten Cate. (2012) InforMatrix: ADP antagonists in acute coronary syndromes. Expert Opinion on Pharmacotherapy1-29
CrossRef25
Karthik Balasubramaniam, Girish N. Viswanathan, Sally M. Marshall, Azfar G. Zaman. (2012) Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. Cardiology Research and Practice 2012, 1-18
CrossRef26
GENNARO SARDELLA, MASSIMO MANCONE, GIUSEPPE BIONDI-ZOCCAI, GIULIA CONTI, EMANUELE CANALI, ROCCO STIO, LUIGI LUCISANO, SIMONE CALCAGNO, CARLOTTA DE CARLO, FRANCESCO FEDELE. (2012) Beneficial Impact of Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation. Journal of Interventional Cardiologyno-no
CrossRef27
Masako YAMAZAKI, Shinichiro UCHIYAMA. (2012) Antithrombotic and thrombolytic therapy for ischemic stroke. Japanese Journal of Thrombosis and Hemostasis 23:1, 16-24
CrossRef28
Ayman El-Menyar, Khalid F. AlHabib, Ahmed Al-Motarreb, Ahmad Hersi, Hussam Al Faleh, Nidal Asaad, Shukri Al Saif, Wael Almahmeed, Kadhim Sulaiman, Haitham Amin, Jawad Al-Lawati, Alawi A. Alsheikh-Ali, Awad AlQahtani, Norah Q. Al-Sagheer, Rajvir Singh, Jassim Al Suwaidi. (2012) Prior Antiplatelet Use and Cardiovascular Outcomes in Patients Presenting with Acute Coronary Syndromes. American Journal Cardiovascular Drugs1
CrossRef29
Matthew S. West, Ethan U. Cumbler. (2012) Acute Ischemic Stroke. Hospital Medicine Clinics
CrossRef30
Udaya S. Tantry, Eliano P. Navarese, Paul A. Gurbel. (2012) Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. Interventional Cardiology Clinics 1:2, 223
CrossRef31
Bruce A. Warden, Alana M. Willman, Craig D. Williams. (2012) Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nature Reviews Neurology
CrossRef32
Larry B. Goldstein. 2012. Prevention and Management of Stroke. , 1359-1367.
CrossRef33
J. Michael Gaziano, Paul M Ridker, Peter Libby. 2012. Primary and Secondary Prevention of Coronary Heart Disease. , 1010-1035.
CrossRef34
Marco Roffi, Michael Braendle. 2012. Diabetes. , 30-49.
CrossRef35
David A. Morrow, William E. Boden. 2012. Stable Ischemic Heart Disease. , 1210-1269.
CrossRef36
Jeffrey I. Weitz. 2012. Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease. , 1844-1867.
CrossRef37
Curtiss T. Stinis. 2012. Intervention for Non-ST-Segment Elevation Acute Coronary Syndromes. , 223-236.
CrossRef38
Mark A. Creager, Peter Libby. 2012. Peripheral Artery Diseases. , 1338-1358.
CrossRef39
Matthew J. Price, Dominick J. Angiollilo. 2012. Platelet Inhibitor Agents. , 97-112.
CrossRef40
Ki-Nam Shim. (2012) Does Low Dose Aspirin Increase Gastrointestinal Bleeding?. The Korean Journal of Gastroenterology 59:4, 324
CrossRef41
Justin A. Zivin. 2012. Ischemic Cerebrovascular Disease. , 2310-2320.
CrossRef42
Sam Schulman, Jack Hirsh. 2012. Antithrombotic Therapy. , 171-177.
CrossRef43
William E. Boden. 2012. Angina Pectoris and Stable Ischemic Heart Disease. , 412-425.
CrossRef44
Thomas Cuisset, Pierre-Emmanuel Morange, Marie-Christine Alessi. (2011) Recent advances in the pharmacogenetics of clopidogrel. Human Genetics
CrossRef45
Kirtiman Srivastava, Philip M. W. Bath, Ulvi Bayraktutan. (2011) Current Therapeutic Strategies to Mitigate the eNOS Dysfunction in Ischaemic Stroke. Cellular and Molecular Neurobiology
CrossRef46
Paul A. Gurbel, Udaya S. Tantry. 2011. Resistance to Antiplatelet Therapy. .
CrossRef47
Karin Mauer, Jorge F. Saucedo. 2011. Cardiology-In-Depth Look: Advances in Antiplatelet Therapy. .
CrossRef48
Dushyant Singh, Alexandra S. Laya, Omkar U. Vaidya, Syed A. Ahmed, Aaron J. Bonham, Wendell K. Clarkston. (2011) Risk of Bleeding After Percutaneous Endoscopic Gastrostomy (PEG). Digestive Diseases and Sciences
CrossRef49
Leonardo Bolognese, Dominick J. Angiolillo. (2011) Unravelling the benefit against the risk of long-term dual antiplatelet therapy. Current Opinion in Cardiology 26, S22-S30
CrossRef50
N. Diehm, J. Schmidli, C. Setacci, J.-B. Ricco, G. de Donato, F. Becker, H. Robert-Ebadi, P. Cao, H.H. Eckstein, P. De Rango, M. Teraa, F.L. Moll, F. Dick, A.H. Davies, M. Lepäntalo, J. Apelqvist. (2011) Chapter III: Management of Cardiovascular Risk Factors and Medical Therapy. European Journal of Vascular and Endovascular Surgery 42, S33-S42
CrossRef51
A. D. Michelson. (2011) Advances in Antiplatelet Therapy. Hematology 2011:1, 62-69
CrossRef52
Mathieu Pankert, Jacques Quilici, Thomas Cuisset. (2011) Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. Journal of Cardiovascular Translational Research
CrossRef53
, , M. Tendera, V. Aboyans, M.-L. Bartelink, I. Baumgartner, D. Clement, J.-P. Collet, A. Cremonesi, M. De Carlo, R. Erbel, F. G. R. Fowkes, M. Heras, S. Kownator, E. Minar, J. Ostergren, D. Poldermans, V. Riambau, M. Roffi, J. Rother, H. Sievert, M. van Sambeek, T. Zeller, , J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, , P. Kolh, A. Torbicki, S. Agewall, A. Blinc, M. Bulvas, F. Cosentino, T. De Backer, A. Gottsater, D. Gulba, T. J. Guzik, B. Jonsson, G. Kesmarky, A. Kitsiou, W. Kuczmik, M. L. Larsen, J. Madaric, J.-L. Mas, J. J. V. McMurray, A. Micari, M. Mosseri, C. Muller, R. Naylor, B. Norrving, O. Oto, T. Pasierski, P.-F. Plouin, F. Ribichini, J.-B. Ricco, L. Ruilope, J.-P. Schmid, U. Schwehr, B. G. M. Sol, M. Sprynger, C. Tiefenbacher, C. Tsioufis, H. Van Damme. (2011) ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal 32:22, 2851-2906
CrossRef54
M. Roffi, D. J. Angiolillo, A. P. Kappetein. (2011) Current concepts on coronary revascularization in diabetic patients. European Heart Journal 32:22, 2748-2757
CrossRef55
Barbara J. Messinger-Rapport, John E. Morley, David R. Thomas, Julie K. Gammack. (2011) Clinical Update on Nursing Home Medicine: 2011. Journal of the American Medical Directors Association 12:9, 615-626.e6
CrossRef56
Serkan Ozben, Beste Ozben, Azra Meryem Tanrikulu, Feriha Ozer, Tomris Ozben. (2011) Aspirin resistance in patients with acute ischemic stroke. Journal of Neurology 258:11, 1979-1986
CrossRef57
Satyendra Giri. (2011) Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy. International Journal of Cardiology
CrossRef58
Thom W. Rooke, Alan T. Hirsch, Sanjay Misra, Anton N. Sidawy, Joshua A. Beckman, Laura K. Findeiss, Jafar Golzarian, Heather L. Gornik, Jonathan L. Halperin, Michael R. Jaff, Gregory L. Moneta, Jeffrey W. Olin, James C. Stanley, Christopher J. White, John V. White, R. Eugene Zierler. (2011) 2011 ACCF/AHA Focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline). Journal of Vascular Surgery 54:5, e32-e58
CrossRef59
Thom W. Rooke, Alan T. Hirsch, Sanjay Misra, Anton N. Sidawy, Joshua A. Beckman, Laura K. Findeiss, Jafar Golzarian, Heather L. Gornik, Jonathan L. Halperin, Michael R. Jaff, Gregory L. Moneta, Jeffrey W. Olin, James C. Stanley, Christopher J. White, John V. White, R. Eugene Zierler. (2011) 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline). Journal of the American College of Cardiology 58:19, 2020-2045
CrossRef60
Jean-Pierre Bassand. (2011) Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. International Journal of Cardiology
CrossRef61
Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Spertus, James H. Stein, Kathryn A. Taubert. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology
CrossRef62
Saurav Chatterjee, Subhankar Maitra, Anasua Chakraborty. (2011) Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal
CrossRef63
C. Patrono, F. Andreotti, H. Arnesen, L. Badimon, C. Baigent, J.-P. Collet, R. De Caterina, D. Gulba, K. Huber, S. Husted, S. D. Kristensen, J. Morais, F.-J. Neumann, L. H. Rasmussen, A. Siegbahn, P.-G. Steg, R. F. Storey, F. Van de Werf, F. Verheugt. (2011) Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal
CrossRef64
Adnan Kastrati, Robert A. Byrne, Stefanie Schulz. (2011) Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation?. JACC: Cardiovascular Interventions 4:10, 1129-1132
CrossRef65
Ernesto Oqueli, Ron Dick. (2011) Percutaneous Coronary Intervention in Very Elderly Patients. In-hospital Mortality and Clinical Outcome. Heart, Lung and Circulation 20:10, 622-628
CrossRef66
K-H Jung, K Chu, S-T Lee, H-J Yoon, J-Y Chang, W-S Nam, S-H Yoon, J-Y Cho, K-S Yu, I-J Jang, M Kim, S K Lee, J-K Roh. (2011) Prolonged Use of Aspirin Alters Human and Rat Intestinal Cells and Thereby Limits the Absorption of Clopidogrel. Clinical Pharmacology & Therapeutics 90:4, 612-619
CrossRef67
Jesse Dawson, Terry Quinn, Mark Rafferty, Peter Higgins, Gautamanda Ray, Kennedy R. Lees, Matthew R. Walters. (2011) Aspirin Resistance and Compliance with Therapy. Cardiovascular Therapeutics 29:5, 301-307
CrossRef68
Shoichiro Daimon, Hidenobu Terai. (2011) Influence of Antiplatelet Medications on Bleeding Events in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 15:5, 454-459
CrossRef69
Kurt Samson. (2011) NINDS Halts the Aspirin-Clopidogrel Arm of Stroke Trial. Neurology Today 11:20, 1
CrossRef70
Helmi Lutsep. (2011) Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke. Expert Review of Cardiovascular Therapy 9:10, 1295-1303
CrossRef71
Majid M Mughal, Mohsin K Khan, J Kevin DeMarco, Arshad Majid, Fadi Shamoun, George S Abela. (2011) Symptomatic and asymptomatic carotid artery plaque. Expert Review of Cardiovascular Therapy 9:10, 1315-1330
CrossRef72
Teddy Kosoglou, Larisa Reyderman, Renger G. Tiessen, André A. Vliet, Robert R. Fales, Robert Keller, Bo Yang, David L. Cutler. (2011) Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. European Journal of Clinical Pharmacology
CrossRef73
Arun Kalyanasundaram, A. Michael Lincoff. (2011) Managing adverse effects and drug–drug interactions of antiplatelet agents. Nature Reviews Cardiology 8:10, 592-600
CrossRef74
M.J. Cohen. (2011) Does CYP2C19 inhibition lead to clopidogrel thrombogenicity?. Medical Hypotheses 77:3, 448-450
CrossRef75
Gianluca Campo, Matteo Miccoli, Matteo Tebaldi, Jlenia Marchesini, Luca Fileti, Monia Monti, Marco Valgimigli, Roberto Ferrari. (2011) Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 22:6, 399-407
CrossRef76
Antonella Boni, Valentina Riva, Elisabetta Galloni, Francesco Perini. (2011) Attività piastrinica residua e fallimento clinico della profilassi antitrombotica nell’attacco ischemico cerebrale acuto. La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine 7:3, 163-169
CrossRef77
Amir Lotfi, Jiang Cui, Siddharth Wartak, Jesse Columbo, Scott Mulvey, Mary Davis, Marc Schweiger, Gregory R. Giugliano. (2011) Influence of Low-Dose Aspirin (81 mg) on the Incidence of Definite Stent Thrombosis in Patients Receiving Bare-Metal and Drug-Eluting Stents. Clinical Cardiology 34:9, 567-571
CrossRef78
Claudio Baracchini, Mario Gruppo, Franco Mazzalai, Renata Lorenzetti, Giorgio Meneghetti, Enzo Ballotta. (2011) Predictors of neck bleeding after eversion carotid endarterectomy. Journal of Vascular Surgery 54:3, 699-705
CrossRef79
John J. Ricotta, Ali AbuRahma, Enrico Ascher, Mark Eskandari, Peter Faries, Brajesh K. Lal. (2011) Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery 54:3, e1-e31
CrossRef80
Angel Lanas, Ping Wu, Jennie Medin, Edward J. Mills. (2011) Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-Analysis. Clinical Gastroenterology and Hepatology 9:9, 762-768.e6
CrossRef81
Sebastien Armero, Laurent Bonello, Julie Berbis, Laurence Camoin-Jau, Gilles Lemesle, Laurent Jacquin, Caroline Bonello-Burignat, Michel Pansieri, Frederic Collet, Michel Ostorero, Françoise Dignat-George, Franck Paganelli. (2011) Rate of Nuisance Bleedings and Impact on Compliance to Prasugrel in Acute Coronary Syndromes. The American Journal of Cardiology
CrossRef82
Haralampos J. Milionis, Grigorios Gerotziafas, Michael S. Kostapanos, Anastasia Vemmou, Panagiotis Zis, Konstantinos Spengos, Moses Elisaf, Konstantinos N. Vemmos. (2011) Clopidogrel vs. Aspirin Treatment on Admission Improves 5-Year Survival After a First-ever Acute Ischemic Stroke. Data from the Athens Stroke Outcome Project. Archives of Medical Research
CrossRef83
B. Fuentes, J. Gállego, A. Gil-Nuñez, A. Morales, F. Purroy, J. Roquer, T. Segura, J. Tejada, A. Lago, E. Díez-Tejedor. (2011) Guía para el tratamiento preventivo del ictus isquémico y AIT (II). Recomendaciones según subtipo etiológico. Neurología
CrossRef84
Fadi B. Nahab, Sakib Qureshi. 2011. Antithrombotics for Ischemic Stroke. , 205-222.
CrossRef85
Michael Kornfeld, Joseph R. Munsayac. 2011. Antiplatelet Medications. , 47-65.
CrossRef86
Alessandro Squizzato, Erica Romualdi, Francesco Dentali, Walter Ageno, Alessandro Squizzato. 2011. Statins for acute ischemic stroke. .
CrossRef87
Suzanne V. Arnold, David J. Cohen, Elizabeth A. Magnuson. (2011) Cost-effectiveness of oral antiplatelet agents—current and future perspectives. Nature Reviews Cardiology 8:10, 580-591
CrossRef88
Philip Joseph, Koon Teo. (2011) Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. Current Cardiology Reports 13:4, 287-295
CrossRef89
Sharon Poisson, S. Claiborne Johnston. (2011) Prevention of Stroke Following Transient Ischemic Attack. Current Atherosclerosis Reports 13:4, 330-337
CrossRef90
Christopher W. Good, Peter B. Berger. (2011) P2Y12 Antagonists in Acute Coronary Syndrome: In Whom Should They Be Started, and When?. Current Cardiology Reports 13:4, 320-326
CrossRef91
Madhan Shanmugasundaram, Vinny K. Ram, Ulrich C. Luft, Molly Szerlip, Joseph S. Alpert. (2011) Peripheral Arterial Disease-What Do We Need to Know?. Clinical Cardiology 34:8, 478-482
CrossRef92
M. Endres, M. Grond, W. Hacke, M. Ebinger, P.D. Schellinger, M. Dichgans. (2011) Grenzentscheidungen in der Schlaganfalltherapie. Der Nervenarzt 82:8, 957-972
CrossRef93
Sandra L. Close. (2011) Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?. Fundamental & Clinical Pharmacologyno-no
CrossRef94
Omair Yousuf, Deepak L. Bhatt. (2011) The evolution of antiplatelet therapy in cardiovascular disease. Nature Reviews Cardiology 8:10, 547-559
CrossRef95
James A. Richter, James T. Patrie, Robert P. Richter, Zachary H. Henry, George H. Pop, Kara A. Regan, David A. Peura, Robert G. Sawyer, Patrick G. Northup, Andrew Y. Wang. (2011) Bleeding after percutaneous endoscopic gastrostomy is linked to serotonin reuptake inhibitors, not aspirin or clopidogrel. Gastrointestinal Endoscopy 74:1, 22-34.e1
CrossRef96
Samuel Yip, Oscar Benavente. (2011) Antiplatelet Agents for Stroke Prevention. Neurotherapeutics 8:3, 475-487
CrossRef97
Ken Butcher, J. Max Findlay. (2011) Management of Antithrombotic-Associated Intracerebral Hemorrhage. World Neurosurgery 76:1-2, 59-60
CrossRef98
Hidetoshi Matsukawa, Masaki Shinoda, Daisuke Yamamoto, Motoharu Fujii, Atsushi Murakata, Ryoichi Ishikawa, Fumio Omata. (2011) Antiplatelet Agents Are Risk Factors for Cerebellar Hemorrhage in Patients With Primary Intracerebral Hemorrhage. Journal of Stroke and Cerebrovascular Diseases 20:4, 346-351
CrossRef99
Peter G. Campbell, Sanjay Yadla, Anish N. Sen, Jack Jallo, Pascal Jabbour. (2011) Emergency Reversal of Clopidogrel in the Setting of Spontaneous Intracerebral Hemorrhage. World Neurosurgery 76:1-2, 100-104
CrossRef100
Marc I. Chimowitz, Michael J. Lynn, Tanya N. Turan, David Fiorella, Bethany F. Lane, Scott Janis, Colin P. Derdeyn. (2011) Design of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial. Journal of Stroke and Cerebrovascular Diseases 20:4, 357-368
CrossRef101
Fadi Nahab, Carlene Kingston, Michael R. Frankel, Jacques E. Dion, C. Michael Cawley, Brian Mitchell, L. Paige Hammonds, Lauren Ayala, Frank C. Tong. (2011) Early Aggressive Medical Management for Patients with Symptomatic Intracranial Stenosis. Journal of Stroke and Cerebrovascular Diseases
CrossRef102
Jeffrey S. Berger, Anuradha Lala, Mori J. Krantz, Gizelle S. Baker, William R. Hiatt. (2011) Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials. American Heart Journal 162:1, 115-124.e2
CrossRef103
Sanjay Gandhi, Ido Weinberg, Ronan Margey, Michael R. Jaff. (2011) Comprehensive Medical Management of Peripheral Arterial Disease. Progress in Cardiovascular Diseases 54:1, 2-13
CrossRef104
PH. G. STEG, S. H. DORMAN, P. AMARENCO. (2011) Atherothrombosis and the role of antiplatelet therapy. Journal of Thrombosis and Haemostasis 9, 325-332
CrossRef105
Ryo Itabashi, Etsuro Mori, Eisuke Furui, Shoichiro Sato, Yukako Yazawa, Satoru Fujiwara. (2011) Combination oral antiplatelet therapy may increase the risk of hemorrhagic complications in patients with acute ischemic stroke caused by large artery disease. Thrombosis Research
CrossRef106
Deborah Bergman. (2011) Preventing recurrent cerebrovascular events in patients with stroke or transient ischemic attack: The current data. Journal of the American Academy of Nurse Practitionersno-no
CrossRef107
Jeffrey S. Berger, Deepak L. Bhatt, P. Gabriel Steg, Steven R. Steinhubl, Gilles Montalescot, Mingyuan Shao, Werner Hacke, Keith A. Fox, Peter B. Berger, Eric J. Topol, A. Michael Lincoff. (2011) Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal 162:1, 98-105.e1
CrossRef108
Mitchell D. Weinberg, Joe F. Lau, Kenneth Rosenfield, Jeffrey W. Olin. (2011) Peripheral artery disease. Part 2: medical and endovascular treatment. Nature Reviews Cardiology 8:8, 429-441
CrossRef109
Nadish Garg, Naveen Rajpurohit, Greg Flaker. (2011) Clopidogrel hydrogen sulphate for atrial fibrillation. Expert Opinion on Pharmacotherapy1-7
CrossRef110
Robert Guthrie. (2011) Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. Advances in Therapy 28:6, 473-482
CrossRef111
Jaime Gállego Culleré, María Elena Erro Aguirre. (2011) Basilar Branch Occlusion. Current Treatment Options in Cardiovascular Medicine 13:3, 247-260
CrossRef112
Virginia A. Pujol Lereis, Sebastian Ameriso, Guillermo P. Povedano, Sebastián F. Ameriso. (2011) Ischemic Stroke in Patients Receiving Aspirin. Journal of Stroke and Cerebrovascular Diseases
CrossRef113
Andrew Cunningham, C. Michael Stein, Cecilia P. Chung, James R. Daugherty, Walter E. Smalley, Wayne A. Ray. (2011) An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiology and Drug Safety 20:6, 560-566
CrossRef114
Stephen H. McKellar, Stuart Abel, Christopher L. Camp, Rakesh M. Suri, Mark H. Ereth, Hartzell V. Schaff. (2011) Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. The Journal of Thoracic and Cardiovascular Surgery 141:6, 1410-1416
CrossRef115
Schwartz, Robert S., , Borissoff, Julian Ilcheff, Spronk, Henri M.H., ten Cate, Hugo, . (2011) The Hemostatic System as a Modulator of Atherosclerosis. New England Journal of Medicine 364:18, 1746-1760
Full Text116
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Journal of the American College of Cardiology 57:19, 1920-1959
CrossRef117
Barbara J. Zarowitz. (2011) Anticoagulant Polypharmacy. Geriatric Nursing 32:3, 198-202
CrossRef118
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef119
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, Alexander G.G. Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology 27:3, S1-S59
CrossRef120
Peter M Rothwell, Ale Algra, Pierre Amarenco. (2011) Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. The Lancet 377:9778, 1681-1692
CrossRef121
L.M. Salmerón Febres, B. Al-Raies Bolaños, J.I. Blanes Mompó, G. Collado Bueno, J. Cuenca Manteca, S. Fernandez Gonzalez, J.P. Linares Palomino, C. López Espada, J. Martínez Gámez, J. Serrano Hernando. (2011) Guía de actuación en técnicas y procedimientos endovasculares del sector infrainguinal. Angiología 63:3, 119-142
CrossRef122
Jonathan A. Rapp, Anil Verma, Tyrone J. Collins. 2011. Intracranial Vertebral Artery Stenting. , 427-435.
CrossRef123
P. P. HAO, M. X. ZHANG, R. J. LI, J. M. YANG, J. L. WANG, Y. G. CHEN, Y. ZHANG. (2011) Clopidogrel 150 vs. 75 mg day−1 in patients undergoing percutaneous coronary intervention: a meta-analysis. Journal of Thrombosis and Haemostasis 9:4, 627-637
CrossRef124
Mireille Astrid Moise, Vikram S. Kashyap. (2011) Treatment of Aortoiliac Occlusive Disease: Medical versus Endovascular versus Surgical Therapy. Current Treatment Options in Cardiovascular Medicine 13:2, 114-128
CrossRef125
Oscar R. Benavente, Carole L. White, Lesly Pearce, Pablo Pergola, Ana Roldan, Marie-France Benavente, Christopher Coffey, Leslie A. McClure, Jeff M. Szychowski, Robin Conwit, Patricia A. Heberling, George Howard, Carlos Bazan, Gabriela Vidal-Pergola, Robert Talbert, Robert G. Hart, . (2011) The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke 6:2, 164-175
CrossRef126
R. A. Ajjan, Peter J. Grant. (2011) The Role of Antiplatelets in Hypertension and Diabetes Mellitus. The Journal of Clinical Hypertension 13:4, 305-313
CrossRef127
Harvey D. White. (2011) Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. American Heart Journal 161:3, 450-461
CrossRef128
Ping–I. Hsu, Kwok–Hung Lai, Chun–Peng Liu. (2011) Esomeprazole With Clopidogrel Reduces Peptic Ulcer Recurrence, Compared With Clopidogrel Alone, in Patients With Atherosclerosis. Gastroenterology 140:3, 791-798.e2
CrossRef129
Jersey Chen, Chunxue Shi, Elizabeth M. Mahoney, Elizabeth Schneider Dunn, Stéphane Rinfret, J. Jaime Caro, Judith O'Brien, Wissam El-Hadi, Deepak L. Bhatt, Eric J. Topol, David J. Cohen. (2011) Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial. Canadian Journal of Cardiology 27:2, 222-231
CrossRef130
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, A. Graham Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. Canadian Journal of Cardiology 27:2, 208-221
CrossRef131
Philip Urban, Alexandre Abizaid, Adrian Banning, Antonio L. Bartorelli, Ana Cebrian Baux, Vladimír Džavík, Stephen Ellis, Runlin Gao, David Holmes, Myung Ho Jeong, Victor Legrand, Franz-Josef Neumann, Maria Nyakern, Christian Spaulding, Stephen Worthley. (2011) Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population. Journal of the American College of Cardiology 57:13, 1445-1454
CrossRef132
M. MAUFUS, J. B. GUITTON, G. VANZETTO, L. BELLE, B. IMBERT, G. PERNOD. (2011) Prognostic value of the ankle-brachial index in patients with stable chronic cardiovascular disease. Journal of Thrombosis and Haemostasis 9:3, 610-612
CrossRef133
Udaya S Tantry, Dean J Kereiakes, Paul A Gurbel. (2011) Role of ticagrelor in the treatment of coronary artery disease. Clinical Investigation 1:3, 429-437
CrossRef134
M. Cattaneo. (2011) The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 117:7, 2102-2112
CrossRef135
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Journal of the American College of Cardiology 57:8, e16-e94
CrossRef136
Thalia S. Field, Oscar R. Benavente. (2011) Current Status of Antiplatelet Agents to Prevent Stroke. Current Neurology and Neuroscience Reports 11:1, 6-14
CrossRef137
Fiona Foo, Keith G Oldroyd. (2011) Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. Biomarkers in Medicine 5:1, 9-30
CrossRef138
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. Journal of the American College of Cardiology 57:8, 1002-1044
CrossRef139
Graeme J. Hankey, S. Claiborne Johnston, J. Donald Easton, Werner Hacke, Jean-Louis Mas, Danielle Brennan, Koon Hou Mak, Deepak L. Bhatt, Keith A. A. Fox, Eric J. Topol, . (2011) Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. International Journal of Stroke 6:1, 3-9
CrossRef140
Ada Stefanescu, Stephen D. Wiviott. (2011) Considerations Regarding Antiplatelet Therapy in the Elderly. Current Cardiovascular Risk Reports 5:1, 86-95
CrossRef141
Giuseppe Patti, Domenico Grieco, Giordano Dicuonzo, Vincenzo Pasceri, Annunziata Nusca, Germano Di Sciascio. (2011) High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Inflammation. Journal of the American College of Cardiology 57:7, 771-778
CrossRef142
Alessandro Squizzato, Tymen Keller, Erica Romualdi, Saskia Middeldorp, Alessandro Squizzato. 2011. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. .
CrossRef143
A. S. C. Yong, G. J. Pennings, M. Chang, A. Hamzah, T. Chung, M. Qi, D. Brieger, M. Behnia, S. A. Krilis, M. K. C. Ng, H. C. Lowe, L. Kritharides. (2011) Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel. Blood 117:1, 11-20
CrossRef144
Lina Badimon, Gemma Vilahur. (2011) Beneficio clínico de las estatinas: ¿hemos cubierto todo el espectro?. Revista Española de Cardiología Suplementos 11, 3-13
CrossRef145
Oh Young Bang. (2011) Biomarkers of Stroke. Korean Journal of Stroke 13:2, 57
CrossRef146
A.M. Mellett, R.K. Nakamura, D. Bianco. (2011) A Prospective Study of Clopidogrel Therapy in Dogs with Primary Immune-Mediated Hemolytic Anemia. Journal of Veterinary Internal Medicine 25:1, 71-75
CrossRef147
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor, Alice K. Jacobs, Sidney C. Smith, Jeffery L. Anderson, Cynthia D. Adams, Nancy Albert, Christopher E. Buller, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Sharon Ann Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick A. Nishimura, E. Magnus Ohman, Richard L. Page, Barbara Riegel, William G. Stevenson, Lynn G. Tarkington, Clyde W. Yancy. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef148
Y. B
jot, M. Giroud, E. Touz
CrossRef149
Jesse Dawson, Terry Quinn, Kennedy R. Lees, Matthew R. Walters. (2011) Microembolic Signals and Aspirin Resistance in Patients with Carotid Stenosis. Cardiovascular Therapeuticsno-no
CrossRef150
Robert W Yeh, Malini Chandra, Charles E McCulloch, Alan S Go. (2011) Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. BMC Medicine 9:1, 78
CrossRef151
Suh Eun Bae, Seong-Eun Kim, Sung-Ae Jung, So Yoon Yoon, Ki-Nam Shim, Hye-Kyung Jung, Tae Hun Kim, Kwon Yoo, Il Hwan Moon. (2011) The Effect of Aspirin Alone or Aspirin Plus Additional Antiplatelets Therapy on Upper Gastrointestinal Hemorrhage. The Korean Journal of Gastroenterology 57:4, 213
CrossRef152
Masafumi Ueno, Murali Kodali, Antonio Tello-Montoliu, Dominick Joseph Angiolillo. (2011) Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis 18:6, 431-442
CrossRef153
Akinori Sairaku, Yukiko Nakano, Shin Eno, Tatsuya Hondo, Keiji Matsuda, Tomohiko Kisaka, Yasuki Kihara. (2011) Platelet Function Measured Using a Whole Blood Aggregometer Can Predict Bleeding Events. Journal of Atherosclerosis and Thrombosis 18:1, 16-23
CrossRef154
Masamitsu Shimazawa, Hideaki Hara. (2011) Novel Situations of Endothelial Injury in Stroke — Mechanisms of Stroke and Strategy of Drug Development: Protective Effects of Antiplatelet Agents Against Stroke. Journal of Pharmacological Sciences 116:1, 30-35
CrossRef155
Nicholaos Kakouros, Jeffrey J. Rade, Antonios Kourliouros, Jon R. Resar. (2011) Platelet Function in Patients with Diabetes Mellitus: From a Theoretical to a Practical Perspective. International Journal of Endocrinology 2011, 1-14
CrossRef156
Narayanaswamy Venketasubramanian, Joachim Röther, Deepak L. Bhatt, Blandine Pasquet, Jean-Louis Mas, Mark J. Alberts, Michael D. Hill, Franz Aichner, P. Gabriel Steg. (2011) Two-Year Vascular Event Rates in Patients with Symptomatic Cerebrovascular Disease: The REACH Registry. Cerebrovascular Diseases 32:3, 254-260
CrossRef157
Giuseppe Musumeci, Roberta Rossini, Corrado Lettieri, Davide Capodanno, Michele Romano, Renato Rosiello, Giulio Guagliumi, Orazio Valsecchi, Antonello Gavazzi, Dominick J. Angiolillo. (2011) Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef158
Harold P. Adams, Patricia H. Davis. 2011. Antithrombotic Therapy for Treatment of Acute Ischemic Stroke. , 971-991.
CrossRef159
Mar Castellanos, Babette B. Weksler, Oscar R. Benavente. 2011. Antiplatelet Therapy for Secondary Prevention of Stroke. , 1147-1172.
CrossRef160
, Thom W. Rooke, Alan T. Hirsch, Sanjay Misra, Anton N. Sidawy, Joshua A. Beckman, Laura K. Findeiss, Jafar Golzarian, Heather L. Gornik, Jonathan L. Halperin, Michael R. Jaff, Gregory L. Moneta, Jeffrey W. Olin, James C. Stanley, Christopher J. White, John V. White, R. Eugene Zierler, , Alan T. Hirsch, Ziv J. Haskal, Norman R. Hertzer, Curtis W. Bakal, Mark A. Creager, Jonathan L. Halperin, Loren F. Hiratzka, William R.C. Murphy, Jeffrey W. Olin, Jules B. Puschett, Kenneth A. Rosenfield, David Sacks, James C. Stanley, Lloyd M. Taylor, Christopher J. White, John V. White, Rodney A. White, , Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (Updating the 2005 guideline). Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef161
G.L. Moneta. (2011) Randomized Controlled Trial of Dual Antiplatelet Therapy in Patients Undergoing Surgery for Critical Limb Ischemia. Yearbook of Vascular Surgery 2011, 76-77
CrossRef162
G.L. Moneta. (2011) Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease: Results From the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial. Yearbook of Vascular Surgery 2011, 68-71
CrossRef163
Jeffrey S. Berger, Emile R. Mohler. 2011. Peripheral Arterial Disease Assessment and Management. , 512-525.
CrossRef164
Jessica M. Peña, Deepak L. Bhatt. 2011. Antiplatelet Therapy. , 69-85.
CrossRef165
Laura Mauri, Dean J. Kereiakes, Sharon-Lise T. Normand, Stephen D. Wiviott, David J. Cohen, David R. Holmes, Sripal Bangalore, Donald E. Cutlip, Michael Pencina, Joseph M. Massaro. (2010) Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. American Heart Journal 160:6, 1035-1041.e1
CrossRef166
David M. Greer. (2010) Aspirin and Antiplatelet Agent Resistance. CNS Drugs 24:12, 1027-1040
CrossRef167
Neena S. Abraham, Mark A. Hlatky, Elliott M. Antman, Deepak L. Bhatt, David J. Bjorkman, Craig B. Clark, Curt D. Furberg, David A. Johnson, Charles J. Kahi, Loren Laine, Kenneth W. Mahaffey, Eamonn M. Quigley, James Scheiman, Laurence S. Sperling, Gordon F. Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology 56:24, 2051-2066
CrossRef168
L. Lorgis, C. Richard, M. Zeller, A. Gudjoncik, P. Buffet, I. L’Huillier, Y. Cottin. (2010) Les anti-agrégants plaquettaires au cours du syndrome coronarien aigu. Données des grandes études. Annales de Cardiologie et d'Angéiologie 59, S47-S55
CrossRef169
Neena S Abraham, Mark A Hlatky, Elliott M Antman, Deepak L Bhatt, David J Bjorkman, Craig B Clark, Curt D Furberg, David A Johnson, Charles J Kahi, Loren Laine, Kenneth W Mahaffey, Eamonn M Quigley, James Scheiman, Laurence S Sperling, Gordon F Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal of Gastroenterology 105:12, 2533-2549
CrossRef170
Bhatt, Deepak L., Cryer, Byron L., Contant, Charles F., Cohen, Marc, Lanas, Angel, Schnitzer, Thomas J., Shook, Thomas L., Lapuerta, Pablo, Goldsmith, Mark A., Laine, Loren, Scirica, Benjamin M., Murphy, Sabina A., Cannon, Christopher P., . (2010) Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine 363:20, 1909-1917
Full Text171
Ofke S van Boxel, Martijn G H van Oijen, Matthijs P Hagenaars, A J P M Smout, Peter D Siersema. (2010) Cardiovascular and Gastrointestinal Outcomes in Clopidogrel Users on Proton Pump Inhibitors: Results of a Large Dutch Cohort Study. The American Journal of Gastroenterology 105:11, 2430-2436
CrossRef172
Tobias Geisler, Karin Mueller, Simon Aichele, Boris Bigalke, Konstantinos Stellos, Patrick Htun, Elena Ninci, Susanne Fateh-Moghadam, Andreas E. May, Meinrad Gawaz. (2010) Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clinical Research in Cardiology 99:11, 743-752
CrossRef173
Hans-Christoph Diener, Christian Weimar, Ralph Weber. (2010) Antiplatelet therapy in secondary stroke prevention - state of the art. Journal of Cellular and Molecular Medicine 14:11, 2552-2560
CrossRef174
Tom Smiley. (2010) Symptomatic coronary artery disease: A call to action for pharmacists. Canadian Pharmacists Journal 143:6, 302-308
CrossRef175
H. S. Kirshner. (2010) Current issues in antiplatelet therapy for stroke prevention: the importance of stroke subtypes and differences between stroke and MI patients. Journal of Neurology 257:11, 1788-1797
CrossRef176
Guillaume Cayla, Jean-Philippe Collet, Johanne Silvain, Gérard Thiefin, France Woimant, Gilles Montalescot. (2010) Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey. International Journal of Cardiology
CrossRef177
I. Cornelissen, D. Palmer, T. David, L. Wilsbacher, C. Concengco, P. Conley, A. Pandey, S. R. Coughlin. (2010) Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proceedings of the National Academy of Sciences 107:43, 18605-18610
CrossRef178
P. A. Ringleb, M.-G. Bousser, G. Ford, P. Bath, M. Brainin, V. Caso, Á. Cervera, A.l Chamorro, Charlotte Cordonnier, L. Csiba, A. Davalos, H.-C. Diener, J. Ferro, W. Hacke, M. Hennerici, M. Kaste, P. Langhorne, K. Lees, D. Leys, J. Lodder, H. S. Markus, J.-L. Mas, H. P. Mattle, K. Muir, B. Norrving, V. Obach, S. Paolucci, E. B. Ringelstein, P. D. Schellinger, J. Sivenius, V. Skvortsova, K. Stibrant Sunnerhagen, L. Thomassen, D. Toni, R.r von Kummer, N. Gunnar Wahlgren, M. F. Walker, J. Wardlaw. 2010. Ischaemic Stroke and Transient Ischaemic Attack. , 101-158.
CrossRef179
Sergio Leonardi, Pierluigi Tricoci, Richard C. Becker. (2010) Thrombin Receptor Antagonists for the Treatment of Atherothrombosis. Drugs 70:14, 1771-1783
CrossRef180
Wei Feng Lu, Wei Mo, Zhenjie Liu, Wei Guo Fu, Da Qiao Guo, Yu Qi Wang, Hou Yan Song. (2010) The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits. Thrombosis Research 126:4, e339-e343
CrossRef181
Olivier Morel, Laurence Kessler, Patrick Ohlmann, Pierre Bareiss. (2010) Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis 212:2, 367-376
CrossRef182
Jill J.F. Belch, John Dormandy. (2010) Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery 52:4, 825-833.e2
CrossRef183
Yukito Shinohara, Yasuo Katayama, Shinichiro Uchiyama, Takenori Yamaguchi, Shunnosuke Handa, Kempei Matsuoka, Yasuo Ohashi, Norio Tanahashi, Hiroko Yamamoto, Chokoh Genka, Yasuhisa Kitagawa, Hideo Kusuoka, Katsuya Nishimaru, Motoo Tsushima, Yukihiro Koretsune, Tohru Sawada, Chikuma Hamada. (2010) Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. The Lancet Neurology 9:10, 959-968
CrossRef184
Ameer E. Hassan, Haralabos Zacharatos, Gabriela Vazquez, Gustavo J. Rodriguez, M. Fareed K. Suri, Ramachandra P. Tummala, Robert A. Taylor, Adnan I. Qureshi. (2010) Low Risk of Intracranial and Systemic Hemorrhages in Patients on Dual Antiplatelet Treatment Beyond 1 Month Following Neuroendovascular Angioplasty and/or Stent Placement. Journal of Neuroimagingno-no
CrossRef185
Samuel Chackalamannil. 2010. Antiplatelet Agents. .
CrossRef186
Daniel Duerschmied, Christoph Bode, Martin Moser. (2010) Clopidogrel in acute coronary syndrome: implications of recent study findings. Expert Review of Cardiovascular Therapy 8:9, 1215-1229
CrossRef187
Elisabeth Mahla, Helfried Metzler, Udaya S. Tantry, Paul A. Gurbel. (2010) Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery. The Annals of Thoracic Surgery 90:3, 1040-1051
CrossRef188
Dimitris Tousoulis, Ioannis Ph. Paroutoglou, Nikolaos Papageorgiou, Marietta Charakida, Christodoulos Stefanadis. (2010) Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacology & Therapeutics 127:2, 108-120
CrossRef189
Tobias Geisler, Meinrad Gawaz, Steven R. Steinhubl, Deepak L. Bhatt, Robert F. Storey, Marcus Flather. (2010) Current strategies in antiplatelet therapy — Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. Pharmacology & Therapeutics 127:2, 95-107
CrossRef190
David Vivas, Dominick J. Angiolillo. (2010) Platelet P2Y12 Receptor Inhibition. American Journal Cardiovascular Drugs 10:4, 217-226
CrossRef191
P.A. Schneider, A.R. Naylor. (2010) Transatlantic Debate. Asymptomatic Carotid Artery Stenosis – Medical Therapy Alone Versus Medical Therapy Plus Carotid Endarterectomy or Stenting. European Journal of Vascular and Endovascular Surgery 40:2, 274-281
CrossRef192
Martin Moser, Christoph Bode. (2010) Antiplatelet therapy for atherothrombotic disease: How can we improve the outcomes?. Journal of Thrombosis and Thrombolysis 30:2, 240-249
CrossRef193
Eric J Topol, Marie-Germaine Bousser, Keith AA Fox, Mark A Creager, Jean-Pierre Despres, J Donald Easton, Christian W Hamm, Gilles Montalescot, P Gabriel Steg, Thomas A Pearson, Eric Cohen, Christophe Gaudin, Bernard Job, Judith H Murphy, Deepak L Bhatt. (2010) Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. The Lancet 376:9740, 517-523
CrossRef194
Peter A. Schneider, A. Ross Naylor. (2010) Asymptomatic carotid artery stenosis—Medical therapy alone versus medical therapy plus carotid endarterectomy or stenting. Journal of Vascular Surgery 52:2, 499-507
CrossRef195
H.- S. Kang, B. J. Kwon, J. E. Kim, M. H. Han. (2010) Preinterventional Clopidogrel Response Variability for Coil Embolization of Intracranial Aneurysms: Clinical Implications. American Journal of Neuroradiology 31:7, 1206-1210
CrossRef196
Alfredo E Rodriguez, Agustina Rodriguez-Granillo. (2010) Stent selection in patients with acute coronary syndromes and unstable coronary lesions. Interventional Cardiology 2:4, 545-557
CrossRef197
(2010) Duration of Clopidogrel Therapy with Drug-Eluting Stents. New England Journal of Medicine 363:5, 488-490
Full Text198
Kevin R. Bainey, Shamir R. Mehta. (2010) Aspirin for Acute Coronary Syndromes: Have We Learned the Correct Dose Yet?. Current Cardiology Reports 12:4, 344-347
CrossRef199
Anne Burdess, Alastair F. Nimmo, O. James Garden, John A. Murie, A. Raymond W. Dawson, Keith A. A. Fox, David E. Newby. (2010) Randomized Controlled Trial of Dual Antiplatelet Therapy in Patients Undergoing Surgery for Critical Limb Ischemia. Annals of Surgery 252:1, 37-42
CrossRef200
Sergio Leonardi, Sunil V. Rao, Robert A. Harrington, Deepak L. Bhatt, C. Michael Gibson, Matthew T. Roe, Janusz Kochman, Kurt Huber, Uwe Zeymer, Mina Madan, Daniel D. Gretler, Matthew W. McClure, Gayle E. Paynter, Vivian Thompson, Robert C. Welsh. (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). American Heart Journal 160:1, 65-72
CrossRef201
Harvey White. (2010) Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes. Current Opinion in Cardiology 25:4, 299-301
CrossRef202
Jean-Sébastien Hulot, Jean-Philippe Collet, Johanne Silvain, Ana Pena, Anne Bellemain-Appaix, Olivier Barthélémy, Guillaume Cayla, Farzin Beygui, Gilles Montalescot. (2010) Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration. Journal of the American College of Cardiology 56:2, 134-143
CrossRef203
Miles W Behan, Derek P Chew, Philip E Aylward. (2010) The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Current Opinion in Cardiology 25:4, 321-328
CrossRef204
Kimberly L Campbell, John R Cohn, Michael P Savage. (2010) Clopidogrel hypersensitivity: clinical challenges and options for management. Expert Review of Clinical Pharmacology 3:4, 553-561
CrossRef205
Jeffrey W. Olin, Brett A. Sealove. (2010) Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management. Mayo Clinic Proceedings 85:7, 678-692
CrossRef206
E. I. Tucker, U. M. Marzec, M. A. Berny, S. Hurst, S. Bunting, O. J. T. McCarty, A. Gruber, S. R. Hanson. (2010) Safety and Antithrombotic Efficacy of Moderate Platelet Count Reduction by Thrombopoietin Inhibition in Primates. Science Translational Medicine 2:37, 37ra45-37ra45
CrossRef207
Yeh, Robert W., Sidney, Stephen, Chandra, Malini, Sorel, Michael, Selby, Joseph V., Go, Alan S., . (2010) Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction. New England Journal of Medicine 362:23, 2155-2165
Full Text208
Carlos G. Santos-Gallego, Jeremías Bayón, Juan José Badimón. (2010) Thrombi of Different Pathologies: Implications for Diagnosis and Treatment. Current Treatment Options in Cardiovascular Medicine 12:3, 274-291
CrossRef209
Sherrie H. Kaplan, John Billimek, Dara H. Sorkin, Quyen Ngo-Metzger, Sheldon Greenfield. (2010) Who Can Respond to Treatment?. Medical Care 48, S9-S16
CrossRef210
William E. Boden, Marcus D. Flather, Deepak L. Bhatt. (2010) Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective. Cardiovascular Drugs and Therapy 24:3, 207-216
CrossRef211
P.M. Mannucci. (2010) Aspirin as antiplatelet agent in diabetes: Cons. European Journal of Internal Medicine 21:3, 154-156
CrossRef212
Li Liu, Fandian Zeng, Xiaohua Zeng, Qingmei Xue, Shaoping Nie, Cailian Kang, Jianhong Wu, Qingyun Kang, Xingao Wang, Xiaoqing Liu, Tao Li, Jun Chen, Qing Li, Rong Xu, Xiaoyan Yang, Hui Kang, Fagang Jiang, Zongtao Li, Xuwu Wang, Li Zhang, Yu Long. (2010) Revaluation of clopidogrel: let the data speak for themselves. Journal of Huazhong University of Science and Technology [Medical Sciences] 30:3, 299-306
CrossRef213
Ashequl M Islam, Pranav M Patel. (2010) Preventing Serious Sequelae After an Acute Coronary Syndrome: The Consequences of Thrombosis Versus Bleeding With Antiplatelet Therapy. Journal of Cardiovascular Pharmacology 55:6, 585-594
CrossRef214
G. Davì, F. Santilli. (2010) Aspirin as antiplatelet agent in diabetes. PROS-. European Journal of Internal Medicine 21:3, 149-153
CrossRef215
2010. References. , 212-228.
CrossRef216
G. Ducrocq, J. S. Wallace, G. Baron, P. Ravaud, M. J. Alberts, P. W. F. Wilson, E. M. Ohman, D. M. Brennan, R. B. D'Agostino, D. L. Bhatt, P. G. Steg, . (2010) Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. European Heart Journal 31:10, 1257-1265
CrossRef217
SL Keir, K Strachan. (2010) Stroke medicine for the geriatrician 2010. Reviews in Clinical Gerontology 20:02, 92-104
CrossRef218
Itsik Ben-Dor, Rebecca Torguson, Mickey Scheinowitz, Yanlin Li, Cedric Delhaye, Kohei Wakabayashi, Gabriel Maluenda, Asmir I. Syed, Sara D. Collins, Manuel A. Gonzalez, Michael A. Gaglia, Zhenyi Xue, Kimberly Kaneshige, Lowell F. Satler, William O. Suddath, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman. (2010) Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. American Heart Journal 159:5, 871-875
CrossRef219
Sergio Coccheri. (2010) Antiplatelet Drugs – Do We Need New Options?. Drugs 70:7, 887-908
CrossRef220
Markku Kaste. (2010) Time matters for reducing risk of stroke. The Lancet Neurology 9:5, 451-453
CrossRef221
Park, Seung-Jung, Park, Duk-Woo, Kim, Young-Hak, Kang, Soo-Jin, Lee, Seung-Whan, Lee, Cheol Whan, Han, Ki-Hoon, Park, Seong-Wook, Yun, Sung-Cheol, Lee, Sang-Gon, Rha, Seung-Woon, Seong, In-Whan, Jeong, Myung-Ho, Hur, Seung-Ho, Lee, Nae-Hee, Yoon, Junghan, Yang, Joo-Young, Lee, Bong-Ki, Choi, Young-Jin, Chung, Wook-Sung, Lim, Do-Sun, Cheong, Sang-Sig, Kim, Kee-Sik, Chae, Jei Keon, Nah, Deuk-Young, Jeon, Doo-Soo, Seung, Ki Bae, Jang, Jae-Sik, Park, Hun Sik, Lee, Keun, . (2010) Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents. New England Journal of Medicine 362:15, 1374-1382
Full Text222
Berger, Peter B., . (2010) Optimal Duration of Clopidogrel Use after Implantation of Drug-Eluting Stents — Still in Doubt. New England Journal of Medicine 362:15, 1441-1443
Full Text223
V. L. Serebruany, D. Atar. (2010) The PLATO trial: do you believe in magic?. European Heart Journal 31:7, 764-767
CrossRef224
James M. Gebel. (2010) Heterogeneity of Efficacy and Safety of Antiplatelet Therapy in Cardiovascular and Cerebrovascular Disease. American Journal Cardiovascular Drugs 10:2, 115-124
CrossRef225
S. SCHULMAN, F. A. SPENCER. (2010) Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. Journal of Thrombosis and Haemostasis 8:4, 641-650
CrossRef226
NEIL GUPTA, RAHUL NAYAK, SCOTT W. GRISOLANO, DANIEL C. BUCKLES, PETER N. TADROS. (2010) Defining Patients at High Risk for Gastrointestinal Hemorrhage after Drug-Eluting Stent Placement: A Cost Utility Analysis. Journal of Interventional Cardiology 23:2, 179-187
CrossRef227
Boris Bigalke, Konstantinos Stellos, Tobias Geisler, Stephan Lindemann, Andreas E. May, Meinrad Gawaz. (2010) Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease. Clinical Research in Cardiology 99:4, 227-233
CrossRef228
J.-H. Lee, J.-K. Cha, S. J. Lee, S.-W. Ha, S. U. Kwon. (2010) Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. European Journal of Neurology 17:3, 434-442
CrossRef229
Graeme J Hankey, John W Eikelboom. (2010) Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. The Lancet Neurology 9:3, 273-284
CrossRef230
Freek W. A. Verheugt. (2010) Novel oral anticoagulants to prevent stroke in atrial fibrillation. Nature Reviews Cardiology 7:3, 149-154
CrossRef231
S.J. Thurston, B. Heeg, F. de Charro, B. van Hout. (2010) Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial. Current Medical Research and Opinion 26:3, 641-651
CrossRef232
Alexandre C. Ferreira, Francisco Yturi Bulcão Macedo. (2010) A review of simple, non-invasive means of assessing peripheral arterial disease and implications for medical management. Annals of Medicine 42:2, 115-126
CrossRef233
Pierre Albaladejo, Charles Marc Samama. (2010) Patients under anti-platelet therapy. Best Practice & Research Clinical Anaesthesiology 24:1, 41-50
CrossRef234
Rahul Sakhuja, Robert W. Yeh, Deepak L. Bhatt. (2010) Antiplatelet Agents in Acute Coronary Syndromes. Current Problems in Cardiology 35:3, 123-170
CrossRef235
Giampaolo Niccoli, Cristina Spaziani, Marcello Marino, Maria Luisa Pontecorvo, Nicola Cosentino, Marco Bacà, Italo Porto, Antonio Maria Leone, Filippo Crea. (2010) Effect of Chronic Aspirin Therapy on Angiographic Thrombotic Burden in Patients Admitted for a First ST-Elevation Myocardial Infarction. The American Journal of Cardiology 105:5, 587-591
CrossRef236
Sanjay Kaul, George A. Diamond. (2010) Trial and Error. Journal of the American College of Cardiology 55:5, 415-427
CrossRef237
Graeme J Hankey. (2010) Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?. Current Opinion in Neurology 23:1, 65-72
CrossRef238
Christine Lu-Emerson, David Likosky, Alpesh Amin, David Tirschwell. (2010) Management of ischemic stroke: Part 2. The inpatient stay. Journal of Hospital Medicine 5:2, 88-93
CrossRef239
H. Böhner, T. Nowak, K. Balzer, U. Klemp. (2010) Antikoagulation nach infrainguinalem Bypass. Gefässchirurgie 15:1, 43-45
CrossRef240
Carl J. Pepine. (2010) Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine 42:1, 19-35
CrossRef241
Ali O. Abualsaud, Mark J. Eisenberg. (2010) Perioperative Management of Patients With Drug-Eluting Stents. JACC: Cardiovascular Interventions 3:2, 131-142
CrossRef242
Carlo Patrono, Bianca Rocca. (2010) The Future of Antiplatelet Therapy in Cardiovascular Disease. Annual Review of Medicine 61:1, 49-61
CrossRef243
Alan D. Michelson. (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nature Reviews Drug Discovery 9:2, 154-169
CrossRef244
Carly Skamra, Rosalind Ramsey-Goldman. (2010) Management of cardiovascular complications in systemic lupus erythematosus. International Journal of Clinical Rheumatology 5:1, 75-100
CrossRef245
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef246
Christopher M WARD. (2010) [Treatment] Platelet inhibitors of the P2Y12 receptor. Japanese Journal of Thrombosis and Hemostasis 21:4, 457-461
CrossRef247
Gregg W Stone. (2010) Ticagrelor in ACS: redefining a new standard of care?. The Lancet 375:9711, 263-265
CrossRef248
Vijay K. Sharma. (2010) Transient ischemic attack associated with stenosis of accessory middle cerebral artery. Clinical Neurology and Neurosurgery 112:1, 88
CrossRef249
Chiaki YOKOTA. (2010) Japanese guidelines for the management of stroke (2009) :. Japanese Journal of Thrombosis and Hemostasis 21:4, 371-377
CrossRef250
William M. Stone, Sailendra G. Naidu, Alyssa Chapital, Samuel R. Money. (2010) Antiplatelet Medications: Old and Emerging Therapies. Annals of Vascular Surgery 24:1, 140-148
CrossRef251
Dai Yamanouchi, Kimihiro Komori. (2010) Eicosapentaenoic Acid as the Gold Standard for Patients With Peripheral Artery Disease?. Circulation Journal 74:7, 1298-1299
CrossRef252
Antonio Fernández-Ortiz, David Vivas, Juan C. García-Rubira. (2010) Tratamiento antitrombótico en diabéticos con síndrome coronario agudo. Revista Española de Cardiología Suplementos 10:4, 42D-48D
CrossRef253
Clotilde Balucani, Kristian Barlinn, Zeljko Zivanovic, Lucilla Parnetti, Mauro Silvestrini, Andrei V. Alexandrov. (2010) Dual Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke: A Ghost from the Past or a New Frontier?. Stroke Research and Treatment 2010, 1-8
CrossRef254
B. Bigalke, K. Stellos, T. Geisler, E. Kremmer, P. Seizer, A. E. May, S. Lindemann, A. Melms, A. Luft, M. Gawaz. (2010) Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. European Journal of Neurology 17:1, 111-117
CrossRef255
Dominick J. Angiolillo, Masafumi Ueno, Shinya Goto. (2010) Basic Principles of Platelet Biology and Clinical Implications. Circulation Journal 74:4, 597-607
CrossRef256
Shinichiro Uchiyama. (2010) Results of the Cilostazol Stroke Prevention Study II (CSPS II), a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients. Rinsho Shinkeigaku 50:11, 832-834
CrossRef257
Nenad Ratkovic, Radoslav Romanovic, Aleksandra Jovelic, Branko Gligic, Saso Rafajlovski, Danilo Vojvodic, Slobodan Obradovic. (2010) Urgent percutaneous coronary intervention leads to a decrease in serum concentrations of soluble CD40 ligand. Vojnosanitetski pregled 67:9, 732-740
CrossRef258
Scott R. Evans. (2010) Fundamentals of clinical trial design. Journal of Experimental Stroke and Translational Medicine 3:1, 19-27
CrossRef259
Jeffrey I. Weitz. 2010. Antithrombotic Agents. , 541-555.
CrossRef260
Piergiorgio Cao, Paola De Rango. 2010. Carotid Artery Disease. , 1469-1486.
CrossRef261
Mikel Sadek, Peter L. Faries. 2010. Infrainguinal Disease. , 1704-1720.
CrossRef262
Timothy F. Kresowik, Harold P. Adams,. 2010. Cerebrovascular Disease. , 1424-1442.
CrossRef263
Firas Al Solaiman, Amjad Almahameed, John R. Bartholomew. 2010. Peripheral Arterial Disease. , 196-204.
CrossRef264
Peter Sheehan. 2010. Atherosclerotic Risk Factors. , 421-433.
CrossRef265
Nimish Vakil. 2010. Peptic Ulcer Disease. , 861-868.
CrossRef266
P. Decavel, E. Medeiros de Bustos, E. Revenco, F. Vuillier, L. Tatu, T. Moulin. (2010) Ematomi intracerebrali spontanei. EMC - Neurologia 10:2, 1-10
CrossRef267
Dong-Ho Shin, In-Ho Chae, Tae-Jin Youn, Sung-Il Cho, Dong-A. Kwon, Jung-Won Suh, Hyuk-Jae Chang, Young-Seok Cho, Woo-Young Chung, Young-Jin Choi. (2009) Reasonable Duration of Clopidogrel Use After Drug-Eluting Stent Implantation in Korean Patients. The American Journal of Cardiology 104:12, 1668-1673
CrossRef268
Patricia A. Howard, James L. Vacek. (2009) Potential Interaction between Clopidogrel and Proton Pump Inhibitors. American Journal Cardiovascular Drugs 9:6, 353-359
CrossRef269
Richard C Becker, James Scheiman, Harold L Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A Johnson, Frances Chan, Neena S Abraham, Eamonn M M Quigley. (2009) Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. The American Journal of Gastroenterology 104:12, 2903-2917
CrossRef270
Edoardo Camenzind, William Wijns, Laura Mauri, Eric Boersma, Keyur Parikh, Volkhard Kurowski, Runlin Gao, Christoph Bode, John P. Greenwood, Anthony Gershlick, William O'Neill, Patrick W. Serruys, Brenda Jorissen, P. Gabriel Steg. (2009) Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. American Heart Journal 158:6, 902-909.e5
CrossRef271
Marc Cohen. (2009) Oral Antiplatelet Therapy for Acute and Chronic Management of NSTE ACS: Residual Ischemic Risk and Opportunities for Improvement. Cardiovascular Drugs and Therapy 23:6, 489-499
CrossRef272
Andrea Brassard. (2009) Identification of patients at risk of ischemic events for long-term secondary prevention. Journal of the American Academy of Nurse Practitioners 21:12, 677-689
CrossRef273
Richard C. Becker, James Scheiman, Harold L. Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A. Johnson, Frances Chan, Neena S. Abraham, Eamonn M.M. Quigley. (2009) Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. Journal of the American College of Cardiology 54:24, 2261-2276
CrossRef274
D. Sander, T. Etgen. (2009) Sekundärprophylaxe des Schlaganfalls nach PRoFESS und SPARCL. Der Internist 50:11, 1227-1238
CrossRef275
Sarah Song, Bruce Ovbiagele. (2009) Management of risk factors for accelerated atherosclerosis. Current Treatment Options in Neurology 11:6, 460-472
CrossRef276
Peter Kriekard, S. Michael Gharacholou, Eric D. Peterson. (2009) Primary and Secondary Prevention of Cardiovascular Disease in Older Adults: A Status Report. Clinics in Geriatric Medicine 25:4, 745-755
CrossRef277
David Rigau Comas, José Álvarez-Sabin, Antonio Gil Núñez, Sonia Abilleira Castells, Francesc Xavier Borras Pérez, Pedro Armario García, Enrique Arrieta Antón, Eugenio Marañón Fernández, Juan Carlos Martí Canales, Ana Morales Ortiz, Juan Carlos Reverter Calatayud, Esther Sancristóbal Velasco, Ivan Solà Arnau, Pablo Alonso Coello. (2009) Guía de práctica clínica sobre prevención primaria y secundaria del ictus. Medicina Clínica 133:19, 754-762
CrossRef278
Jeffrey S. Berger, Deepak L. Bhatt, Christopher P. Cannon, Zhengming Chen, Lixin Jiang, James B. Jones, Shamir R. Mehta, Marc S. Sabatine, Steven R. Steinhubl, Eric J. Topol, Peter B. Berger. (2009) The Relative Efficacy and Safety of Clopidogrel in Women and Men. Journal of the American College of Cardiology 54:21, 1935-1945
CrossRef279
Cathie LM Sudlow, Gillian Mason, James B Maurice, Catherine J Wedderburn, Graeme J Hankey, Cathie LM Sudlow. 2009. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. .
CrossRef280
Christian Weimar, Ralph Weber, Hans-Christoph Diener. (2009) Antithrombotic medication for stroke prevention. Expert Review of Cardiovascular Therapy 7:10, 1245-1254
CrossRef281
C. Diehm, H. Lawall, D. Pittrow. (2009) Screening bei peripherer arterieller Verschlusskrankheit. Gefässchirurgie 14:5, 370-375
CrossRef282
Dmitriy N Feldman, Issam D Moussa. (2009) Efficacy of aspirin for secondary prevention in patients with peripheral artery disease. Expert Review of Cardiovascular Therapy 7:10, 1203-1207
CrossRef283
Pauline D. Watson, Parijat S. Joy, Chileshe Nkonde, Scott E. Hessen, Dean G. Karalis. (2009) Comparison of Bleeding Complications With Omega-3 Fatty Acids + Aspirin + Clopidogrel—Versus—Aspirin + Clopidogrel in Patients With Cardiovascular Disease. The American Journal of Cardiology 104:8, 1052-1054
CrossRef284
Lawrence A. Notaro, Mohammed H. Usman, James F. Burke, Aqeel Siddiqui, Keith R. Superdock, Michael D. Ezekowitz. (2009) Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. Cardiovascular Therapeutics 27:3, 199-215
CrossRef285
Grace A Lin, Rita F Redberg. (2009) Use of stress testing prior to percutaneous coronary intervention in patients with stable coronary artery disease. Expert Review of Cardiovascular Therapy 7:9, 1061-1066
CrossRef286
Zanfina Ademi, Danny Liew, Derek Chew, Greg Conner, Louise Shiel, Mark Nelson, Ash Soman, Gabriel Steg, Deepak L. Bhatt, Christopher Reid, . (2009) Drug Treatment and Cost of Cardiovascular Disease in Australia. Cardiovascular Therapeutics 27:3, 164-172
CrossRef287
Niall JJ MacDougall, Sanjay Amarasinghe, Keith W Muir. (2009) Secondary prevention of stroke. Expert Review of Cardiovascular Therapy 7:9, 1103-1115
CrossRef288
José Biller. (2009) Antiplatelet therapy in ischemic stroke: Variability in clinical trials and its impact on choosing the appropriate therapy. Journal of the Neurological Sciences 284:1-2, 1-9
CrossRef289
Jersey Chen, Deepak L. Bhatt, Elizabeth Schneider Dunn, Chunxue Shi, J. Jaime Caro, Elizabeth M. Mahoney, Sylvie Gabriel, Joseph D. Jackson, Eric J. Topol, David J. Cohen. (2009) Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial. Value in Health 12:6, 872-879
CrossRef290
Andreas Hermann, Imanuel Dzialowski, Roland Koch, Georg Gahn. (2009) Combined anti-platelet therapy with aspirin and clopidogrel: Risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?. Journal of the Neurological Sciences 284:1-2, 155-157
CrossRef291
Alan D Michelson. (2009) New P2Y12 antagonists. Current Opinion in Hematology 16:5, 371-377
CrossRef292
Yuri B. Pride, Stephen D. Wiviott, Jacqueline L. Buros, Cafer Zorkun, M. Umer Tariq, Elliott M. Antman, Eugene Braunwald, C. Michael Gibson. (2009) Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: A TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)–Thrombolysis in Myocardial Infarction (TIMI) 38 Substudy. American Heart Journal 158:3, e21-e26
CrossRef293
Tal Hasin, Alex Sorkin, Walter Markiewicz, Haim Hammerman, Doron Aronson. (2009) Prevalence and Prognostic Significance of Transient, Persistent, and New-Onset Anemia After Acute Myocardial Infarction. The American Journal of Cardiology 104:4, 486-491
CrossRef294
José Ma Lobos Bejarano, Miguel Angel Royo-Bordonada, Carlos Brotons, Luís Álvarez-Sala, Pedro Armario, Antonio Maiques, Dídac Mauricio, Susana Sans, Fernando Villar, Angel Lizcano, Antonio Gil-Núñez, Fernando de Álvaro, Pedro Conthe, Emilio Luengo, Alfonso del Río, Olga Cortés, Ana de Santiago, Miguel A. Vargas, Mercedes Martínez, Vicenta Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Atención Primaria 41:8, 463.e1-463.e24
CrossRef295
Denis L. Clement. (2009) Treatment of hypertension in patients with peripheral arterial disease: An update. Current Hypertension Reports 11:4, 271-276
CrossRef296
Lonneke ML de Lau, Heleen M den Hertog, Evita G van den Herik, Peter J Koudstaal. (2009) Predicting and preventing stroke after transient ischemic attack. Expert Review of Neurotherapeutics 9:8, 1159-1170
CrossRef297
P. G. Steg. (2009) Heart rate management in coronary artery disease: the CLARIFY registry. European Heart Journal Supplements 11:Suppl D, D13-D18
CrossRef298
P L Gross, J I Weitz. (2009) New Antithrombotic Drugs. Clinical Pharmacology & Therapeutics 86:2, 139-146
CrossRef299
Thomas J. Kiernan, Bryan P. Yan, Michael R. Jaff. (2009) Antiplatelet therapy for the primary and secondary prevention of cerebrovascular events in patients with extracranial carotid artery disease. Journal of Vascular Surgery 50:2, 431-439
CrossRef300
Sarah A Spinler. (2009) Safety and Tolerability of Antiplatelet Therapies for the Secondary Prevention of Atherothrombotic Disease. Pharmacotherapy 29:7, 812-821
CrossRef301
David R. Holmes, Dean J. Kereiakes, Neal S. Kleiman, David J. Moliterno, Giuseppe Patti, Cindy L. Grines. (2009) Combining Antiplatelet and Anticoagulant Therapies. Journal of the American College of Cardiology 54:2, 95-109
CrossRef302
Emile R. Mohler. (2009) Combination antiplatelet therapy in patients with peripheral arterial disease: Is the best therapy aspirin, clopidogrel, or both?. Catheterization and Cardiovascular Interventions 74:S1, S1-S6
CrossRef303
Renato Valenti, Guido Parodi, Angela Migliorini. 2009. Platelet Glycoprotein IIb-IIIa Inhibitors. , 67-76.
CrossRef304
Richard V. Milani. (2009) Antiplatelet therapy after endovascular intervention: Does combination therapy really work and what is the optimum duration of therapy?. Catheterization and Cardiovascular Interventions 74:S1, S7-S11
CrossRef305
Joshua A. Beckman. (2009) Antithrombotic therapies in cerebrovascular disease: What should we use as secondary prevention in patients with carotid artery disease?. Catheterization and Cardiovascular Interventions 74:S1, S12-S16
CrossRef306
Alessandro Napoli, Carlo Catalano, Marco Francone, Vincenzo Sciacca, Iacopo Carbone, Cesare Greco, Michele Anzidei, Francesca Antonella Calabrese, Beatrice Cavallo Marincola, Miles A. Kirchin, Annarita Vestri, Marcello Arca, Luigi Iuliano, Roberto Passariello. (2009) Imaging coronary and extracoronary atherosclerosis: feasibility and impact of whole-body computed tomography angiography. European Radiology 19:7, 1704-1714
CrossRef307
Bharat K Kantharia, Arti N Shah. (2009) Combination of clopidogrel and aspirin for reduction of vascular events in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 7:7, 749-753
CrossRef308
Apostolos I. Hatzitolios, Triandafillos P. Didangelos, Anestis T. Zantidis, Konstantinos Tziomalos, George A. Giannakoulas, Dimitrios T. Karamitsos. (2009) Diabetes mellitus and cerebrovascular disease: which are the actual data?. Journal of Diabetes and its Complications 23:4, 283-296
CrossRef309
(2009) Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting. New England Journal of Medicine 360:25, 2672-2675
Full Text310
Shaker A. Mousa, James T. Willerson, Robert P. Giugliano. 2009. Overview of Antiplatelet Therapy. , 399-408.
CrossRef311
J.M. Lobos, M.Á. Royo-Bordonada, C. Brotons, L. Álvarez-Sala, P. Armario, A. Maiques, D. Mauricio, S. Sans, F. Villar, Á. Lizcano, A. Gil-Núñez, F. de Álvaro, P. Conthe, E. Luengo, A. del Río, O. Cortés, A. de Santiago, M.A. Varga, M. Martínez, V. Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Revista Clínica Española 209:6, 279-302
CrossRef312
José M. Lobos, Miguel Ángel Royo-Bordonada, Carlos Brotons, Luis Álvarez-Sala, Pedro Armario, Antonio Maiques, Dídac Mauricio, Susana Sans, Fernando Villar, Ángel Lizcano, Antonio Gil-Núñez, Fernando de Álvaro, Pedro Conthe, Emilio Luengo, Alfonso del Río, Olga Cortés, Ana de Santiago, Miguel A. Vargas, Mercedes Martínez, Vicenta Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Clínica e Investigación en Arteriosclerosis 21:3, 124-150
CrossRef313
Stephen D. Wiviott, Elliott M. Antman. 2009. Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel. , 471-484.
CrossRef314
H.-C. Diener, C. Weimar. (2009) Update of secondary stroke prevention. Nephrology Dialysis Transplantation 24:6, 1718-1724
CrossRef315
Robert P. Giugliano. 2009. Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents. , 19-36.
CrossRef316
Luis Javier Álvarez-Fernández, Manuel Javier Vallina-Victorero Vázquez, María José Ramos Gallo, María Vicente Santiago. (2009) Implicaciones del registro REACH para la cirugía vascular. Medicina Clínica 132, 25-29
CrossRef317
Taketoshi Ogawa, Masami Hashimoto, Yoichi Niitsu, Joseph A. Jakubowski, Yoshiro Tani, Ken-ichi Otsuguro, Fumitoshi Asai, Atsuhiro Sugidachi. (2009) Effects of prasugrel, a novel P2Y12 inhibitor, in rat models of cerebral and peripheral artery occlusive diseases. European Journal of Pharmacology 612:1-3, 29-34
CrossRef318
Dominick J. Angiolillo, Siva Suryadevara. (2009) Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 375-388
CrossRef319
Byron Cryer. (2009) Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy. Gastroenterology Clinics of North America 38:2, 289-303
CrossRef320
Michael J. Schneck. (2009) Understanding the PRoFESS study for secondary stroke prevention. Current Treatment Options in Cardiovascular Medicine 11:3, 221-231
CrossRef321
Martin B. Leon, Dominic J. Allocco, Keith D. Dawkins, Donald S. Baim. (2009) Late Clinical Events After Drug-Eluting Stents. JACC: Cardiovascular Interventions 2:6, 504-512
CrossRef322
J.E. Delgado Almandoz, P.W. Schaefer, N.P. Forero, J.R. Falla, R.G. Gonzalez, J.M. Romero. (2009) Diagnostic Accuracy and Yield of Multidetector CT Angiography in the Evaluation of Spontaneous Intraparenchymal Cerebral Hemorrhage. American Journal of Neuroradiology 30:6, 1213-1221
CrossRef323
Jigar H. Patel, Julie A. Stoner, Arthur Owora, Sunil T. Mathew, Udho Thadani. (2009) Evidence for Using Clopidogrel Alone or in Addition to Aspirin in Post Coronary Artery Bypass Surgery Patients. The American Journal of Cardiology 103:12, 1687-1693
CrossRef324
D. L. Bhatt, E. D. Peterson, R. A. Harrington, F.-S. Ou, C. P. Cannon, C. M. Gibson, N. S. Kleiman, R. G. Brindis, W. F. Peacock, S. J. Brener, V. Menon, S. C. Smith, C. V. Pollack, W. B. Gibler, E. M. Ohman, M. T. Roe, . (2009) Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. European Heart Journal 30:10, 1195-1202
CrossRef325
Zuzana Motovska, Petr Widimsky, Robert Petr, Dana Bilkova, Iuri Marinov, Stanislav Simek, Petr Kala. (2009) Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statinʼs Advantage and the Smoking “Paradox”. Journal of Cardiovascular Pharmacology 53:5, 368-372
CrossRef326
Jan Smid, Ruediger Braun-Dullaeus, Meinrad Gawaz, Harald F Langer. (2009) Platelet interactions as therapeutic targets for prevention of atherothrombosis. Future Cardiology 5:3, 285-296
CrossRef327
Claudio Napoli, Francesco Cacciatore. (2009) Novel Pathogenic Insights in the Primary Prevention of Cardiovascular Disease. Progress in Cardiovascular Diseases 51:6, 503-523
CrossRef328
Erik L Grove, Steen D Kristensen. (2009) Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiology 5:3, 247-258
CrossRef329
Arijit Dasgupta, Steven R. Steinhubl, Deepak L. Bhatt, Peter B. Berger, Mingyuan Shao, Koon-Hou Mak, Keith A.A. Fox, Gilles Montalescot, Michael A. Weber, Steven M. Haffner, Alexios P. Dimas, P. Gabriel Steg, Eric J. Topol. (2009) Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial). The American Journal of Cardiology 103:10, 1359-1363
CrossRef330
Horma Ouldzein, Jérome Roncalli, Walid Zouaoui, Vanina Bongard, Nicolas Boudou, Nicolas Dumonteil, Thibaut Lhermusier, Meyer Elbaz, Jacques Puel, Didier Carrié. (2009) Drug-eluting or bare-metal stents in subjects over 75 years of age: what is the best therapeutic strategy? Data from 460 consecutive patients with 1-year outcome. Cardiovascular Revascularization Medicine 10:2, 94-102
CrossRef331
Carmen Suárez, José Castillo, Enric Esmatjes, Joan Sala, Marc Cairols, Carmen Montoto, Gloria Barberá. (2009) Complicaciones cardiovasculares a un año de seguimiento en pacientes con aterotrombosis. Registro REACH España. Medicina Clínica 132:14, 537-544
CrossRef332
Howard S. Kirshner. (2009) Differentiating ischemic stroke subtypes: Risk factors and secondary prevention. Journal of the Neurological Sciences 279:1-2, 1-8
CrossRef333
James Stulman, Thomas McGinn, Deborah Korenstein. (2009) Clopidogrel for preventing cardiovascular events. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:2, 194-197
CrossRef334
Akira Mende, Jyun-ei Obata, Keita Sano, Mitsumasa Hirano, Yoshinobu Kitta, Yasushi Kodama, Takamitsu Nakamura, Ken-ichi Kawabata, Yukio Saitoh, Daisuke Fujioka, Tsuyoshi Kobayashi, Kaneo Satoh, Yukio Ozaki, Toshiaki Yano, Kiyotaka Kugiyama. (2009) Measurement of the platelet retention rate in a column of collagen-coated beads is useful for the assessment of efficacy of antiplatelet therapy. Thrombosis Research 123:6, 856-861
CrossRef335
Srinivas Iyengar, LeRoy E. Rabbani. (2009) Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists. Journal of Thrombosis and Thrombolysis 27:3, 300-306
CrossRef336
M. Haris U. Usman, Lawrence A. Notaro, Rangadham Nagarakanti, Eric Brahin, Scott Dessain, Edward Gracely, Michael D. Ezekowitz. (2009) Combination Antiplatelet Therapy for Secondary Stroke Prevention: Enhanced Efficacy or Double Trouble?. The American Journal of Cardiology 103:8, 1107-1112
CrossRef337
Koon-Hou Mak, Deepak L. Bhatt, Mingyuan Shao, Graeme J. Hankey, J. Donald Easton, Keith A.A. Fox, Eric J. Topol. (2009) Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. American Heart Journal 157:4, 658-665
CrossRef338
Giuseppe Lanzino, Alejandro A. Rabinstein, Robert D. Brown. (2009) Treatment of Carotid Artery Stenosis: Medical Therapy, Surgery, or Stenting?. Mayo Clinic Proceedings 84:4, 362-368
CrossRef339
G. Lanzino, A. A. Rabinstein, R. D. Brown. (2009) Treatment of Carotid Artery Stenosis: Medical Therapy, Surgery, or Stenting?. Mayo Clinic Proceedings 84:4, 362-368
CrossRef340
Helmi L. Lutsep. (2009) Recent Clinical Trials of Antiplatelet Therapy in Secondary Stroke Prevention: Expectations and Results for Application in Primary Care Settings. The American Journal of Medicine 122:4, S21-S31
CrossRef341
A. ROSTOM, P. MOAYYEDI, R. HUNT, . (2009) Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Alimentary Pharmacology & Therapeutics 29:5, 481-496
CrossRef342
Richard C Becker, David J Moliterno, Lisa K Jennings, Karen S Pieper, Jinglan Pei, Alan Niederman, Khaled M Ziada, Gail Berman, John Strony, Diane Joseph, Kenneth W Mahaffey, Frans Van de Werf, Enrico Veltri, Robert A Harrington. (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. The Lancet 373:9667, 919-928
CrossRef343
Susana Ayyanathan, David Hersh, Neil L. Coplan, Kirk Garratt. (2009) The Problem of Stent Thrombosis Associated With Drug-Eluting Stents and the Optimal Duration of Dual Antiplatelet Therapy. Preventive Cardiology 12:2, 59-64
CrossRef344
Friederike von Lewinski, Joachim Riggert, Walter Paulus. (2009) Towards a Rationale of Platelet Aggregation Monitoring in Stroke Prophylaxis?. Journal of Stroke and Cerebrovascular Diseases 18:2, 111-115
CrossRef345
Jean-Philippe Collet, Gilles Montalescot. (2009) Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: When does the risk outweigh the benefit?. International Journal of Cardiology 133:1, 8-17
CrossRef346
Alan M. Weiss. (2009) Cardiovascular Disease in Women. Primary Care: Clinics in Office Practice 36:1, 73-102
CrossRef347
K. Pels, P. L. Schwimmbeck, P. Rosenthal, C. Loddenkemper, C. Dang-Heine, U. Rauch, H. Martens, H.-P. Schultheiss, R. Dechend, C. Deiner. (2009) Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs. European Journal of Clinical Investigation 39:3, 174-182
CrossRef348
Justin R. Hamilton. (2009) Protease-activated receptors as targets for antiplatelet therapy. Blood Reviews 23:2, 61-65
CrossRef349
David P. Faxon, Jane E. Freedman. (2009) Facts and controversies of aspirin and clopidogrel therapy. American Heart Journal 157:3, 412-422
CrossRef350
Michael Ross, Fadi Nahab. (2009) Management of Transient Ischemia Attacks in the Twenty-First Century. Emergency Medicine Clinics of North America 27:1, 51-69
CrossRef351
Dimitris Tousoulis, Gerasimos Siasos, Christodoulos Stefanadis. (2009) Aspirin resistance: What the cardiologist needs to know?. International Journal of Cardiology 132:2, 153-156
CrossRef352
Herbert D. Aronow, Steven R. Steinhubl, Danielle M. Brennan, Peter B. Berger, Eric J. Topol. (2009) Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 157:2, 369-374
CrossRef353
Deepak L. Bhatt. (2009) Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease. The American Journal of Cardiology 103:3, 11A-19A
CrossRef354
Kazunori Toyoda. (2009) Pharmacotherapy for the Secondary Prevention of Stroke. Drugs 69:6, 633-647
CrossRef355
Ilga Kikule, Gertrude Enina, Zenija Kovaldina. (2009) The Significance of the Ultrasound Parameters of Carotid Artery Atherosclerosis in Neuroangiosurgical Practice. Acta Chirurgica Latviensis 2009:9, 39-44
CrossRef356
Hiroshi YAMAGAMI, Nobuyuki SAKAI. (2009) Antiplatelet Therapy in Carotid Artery Stenting. Japanese Journal of Thrombosis and Hemostasis 20:6, 602-607
CrossRef357
Kazunori TOYODA. (2009) Problems concerning antithrombotic therapy for Japanese patients : Lessons from the Bleeding with Antithrombotic Therapy (BAT) Study. Japanese Journal of Thrombosis and Hemostasis 20:6, 594-601
CrossRef358
Yasuhiro NISHIKAWA. (2009) 4. Clinical Perspectives of New Antiplatelet Drugs. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:6, 273-278
CrossRef359
Hiroshi Yasuda, Masaya Yamada, Susumu Sawada, Yutaka Endo, Kazuaki Inoue, Fuyuki Asano, Youichi Takeyama, Makoto Yoshiba. (2009) Upper Gastrointestinal Bleeding in Patients Receiving Dual Antiplatelet Therapy after Coronary Stenting. Internal Medicine 48:19, 1725-1730
CrossRef360
Yuichiro YANO. (2009) Determinants of thrombin generation, fibrinolytic activity and endothelial dysfunction in dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. Japanese Journal of Thrombosis and Hemostasis 20:1, 48-55
CrossRef361
Cheryl D. Bushnell, Cathleen S. Colón-Emeric. (2009) Secondary Stroke Prevention Strategies for the Oldest Patients. Drugs & Aging 26:3, 209-230
CrossRef362
Oh Young Bang. (2009) Multimodal MRI for Ischemic Stroke: From Acute Therapy to Preventive Strategies. Journal of Clinical Neurology 5:3, 107
CrossRef363
Victoria P. Tan, Bryan P. Yan, Thomas J. Kiernan, Andrew E. Ajani. (2009) Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. Cardiovascular Revascularization Medicine 10:1, 36-44
CrossRef364
H. P. Adams. (2009) Secondary Prevention of Atherothrombotic Events After Ischemic Stroke. Mayo Clinic Proceedings 84:1, 43-51
CrossRef365
2009. Références. , 223-234.
CrossRef366
Leslie R. Ballou, Benjamin W.E. Wang. 2009. Nonsteroidal Anti-inflammatory Drugs. , 833-861.
CrossRef367
BERNARD J. GERSH, LIONEL H. OPIE. 2009. Which Therapy for Which Condition?. , 388-458.
CrossRef368
KEITH A.A. FOX, HARVEY WHITE, JESSICA J.S. OPIE, BERNARD J. GERSH, LIONEL H. OPIE. 2009. Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. , 293-340.
CrossRef369
Arshad Jahangir, Viqar Maria. 2009. CORONARY ARTERY DISEASE. , 321-365.
CrossRef370
G.L. Moneta. (2009) Patients with peripheral arterial disease in the CHARISMA trial. Yearbook of Vascular Surgery 2009, 38-40
CrossRef371
Rodney Bell, Kiwon Lee, Carissa Pineda, David Brock. 2009. STROKE. , 743-752.
CrossRef372
H.-C. Diener, C. Weimar, M. Böhm, C. Bode, M. Grond, J. Röther. (2008) Patienten mit kardialen und zerebralen Durchblutungsstörungen. Der Kardiologe 2:6, 491-499
CrossRef373
Nina C Raju, John W Eikelboom, Jack Hirsh. (2008) Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature Clinical Practice Cardiovascular Medicine 5:12, 766-780
CrossRef374
P. Schiano, J. Monségu. (2008) Angioplastie coronaire chez l’octogénaire. Annales de Cardiologie et d'Angéiologie 57:6, 365-370
CrossRef375
Azeem Latib, Nuccia Morici, John Cosgrave, Flavio Airoldi, Cosmo Godino, Nedy Brambilla, Alaide Chieffo, Erminio Bonizzoni, Mauro Carlino, Francesco Bedogni, Matteo Montorfano, Giuseppe M. Sangiorgi, Carlo Briguori, Antonio Colombo. (2008) Incidence of Bleeding and Compliance on Prolonged Dual Antiplatelet Therapy (Aspirin + Thienopyridine) Following Drug-Eluting Stent Implantation. The American Journal of Cardiology 102:11, 1477-1481
CrossRef376
Probal Roy, Laurent Bonello, Rebecca Torguson, Axel de Labriolle, Gilles Lemesle, Tina L. Pinto Slottow, Daniel H. Steinberg, Kimberly Kaneshige, Zhenyi Xue, Lowell F. Satler, Kenneth M. Kent, William O. Suddath, Augusto D. Pichard, Joseph Lindsay, Ron Waksman. (2008) Impact of “Nuisance” Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation. The American Journal of Cardiology 102:12, 1614-1617
CrossRef377
Deepak L. Bhatt, James Scheiman, Neena S. Abraham, Elliott M. Antman, Francis K.L. Chan, Curt D. Furberg, David A. Johnson, Kenneth W. Mahaffey, Eamonn M. Quigley, Robert A. Harrington, Eric R. Bates, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, Mark A. Hlatky, Sanjay Kaul, Jonathan R. Lindner, David J. Moliterno, Debabrata Mukherjee, Richard S. Schofield, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2008) ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal of Gastroenterology 103:11, 2890-2907
CrossRef378
R. Charles Callison, Harold P. Adams. (2008) Use of Antiplatelet Agents for Prevention of Ischemic Stroke. Neurologic Clinics 26:4, 1047-1077
CrossRef379
S. Husted. (2008) Benefits and risks with antiplatelet therapy: how great a problem is bleeding?. European Heart Journal Supplements 10:Suppl I, I19-I24
CrossRef380
M. Zimarino, R. De Caterina. (2008) Long-term treatment strategies for atherothrombotic disease: do platelets define the course?. European Heart Journal Supplements 10:Suppl I, I8-I13
CrossRef381
Bryan P. Yan, Andrew E. Ajani, Gishel New, Stephen J. Duffy, Omar Farouque, James Shaw, Martin Sebastian, Robert Lew, Angela Brennan, Nick Andrianopoulos, Chris Reid, David J. Clark. (2008) Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry. International Journal of Cardiology 130:3, 374-379
CrossRef382
R. Ostini, D. Hegney, J. M. Mackson, M. Williamson, S. E. Tett. (2008) Why is the use of clopidogrel increasing rapidly in Australia? An exploration of geographical location, age, sex and cardiac stenting rates as possible influences on clopidogrel use. Pharmacoepidemiology and Drug Safety 17:11, 1077-1090
CrossRef383
Jeffrey W. Moses, George Dangas, Roxana Mehran, Gary S. Mintz. (2008) Drug-Eluting Stents in the Real World: How Intravascular Ultrasound Can Improve Clinical Outcome. The American Journal of Cardiology 102:9, 24J-28J
CrossRef384
Subhash Banerjee, Cyril Varghese, Jepsin Samuel, Rick A. Weideman, Bertis B. Little, Kevin C. Kelly, Sunil V. Rao, Robert F. Reilly, Emmanouil S. Brilakis. (2008) Comparison of the Impact of Short (<1 Year) and Long-Term (≥1 Year) Clopidogrel Use Following Percutaneous Coronary Intervention on Mortality. The American Journal of Cardiology 102:9, 1159-1162
CrossRef385
Herbert D. Aronow, Robert M. Califf, Robert A. Harrington, Marc Vallee, Carmelo Graffagnino, Ashfaq Shuaib, Desmond J. Fitzgerald, J. Donald Easton, Frans Van de Werf, Hans-Christoph Diener, James Ferguson, Peter J. Koudstaal, Pierre Amarenco, Pierre Theroux, Stephen Davis, Eric J. Topol. (2008) Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial). The American Journal of Cardiology 102:10, 1285-1290
CrossRef386
V. L. Serebruany, S. Goto. (2008) The challenge of monitoring platelet response after clopidogrel. European Heart Journal 29:23, 2833-2834
CrossRef387
Stephen H. McKellar, Jess L. Thompson, Raul F. Garcia-Rinaldi, Ryan J. MacDonald, Thoralf M. Sundt, Hartzell V. Schaff. (2008) Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: An in vivo study in swine. The Journal of Thoracic and Cardiovascular Surgery 136:4, 908-914
CrossRef388
George Bakris, Michael Böhm, Gilles Dagenais, Hans-Christoph Diener, Toshiro Fujita, Philip Gorelick, Sverre Erik Kjeldsen, Markku Laakso, Giuseppe Mancia, Bertram Pitt, Arya Sharma, Peter Sleight, Koon Teo, Thomas Unger, Michael Weber, Bryan Williams, Faiez Zannad. (2008) Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clinical Research in Cardiology 97:10, 713-725
CrossRef389
P.D. Schellinger, P. Ringleb, W. Hacke. (2008) Leitlinien zum Management von Patienten mit akutem Hirninfarkt oder TIA der Europäischen Schlaganfallorganisation 2008. Der Nervenarzt 79:10, 1180-1202
CrossRef390
Gregory P Van Stavern, Renee B Van Stavern. (2008) Stroke and visual loss. Expert Review of Ophthalmology 3:5, 529-541
CrossRef391
Joseph P Vande Griend, Joseph J Saseen. (2008) Combination Antiplatelet Agents for Secondary Prevention of Ischemic Stroke. Pharmacotherapy 28:10, 1233-1242
CrossRef392
Deepak L. Bhatt, James Scheiman, Neena S. Abraham, Elliott M. Antman, Francis K.L. Chan, Curt D. Furberg, David A. Johnson, Kenneth W. Mahaffey, Eamonn M. Quigley, Robert A. Harrington, Eric R. Bates, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, Mark A. Hlatky, Sanjay Kaul, Jonathan R. Lindner, David J. Moliterno, Debabrata Mukherjee, Richard S. Schofield, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2008) ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology 52:18, 1502-1517
CrossRef393
Gregg W. Stone, Stephen G. Ellis, Antonio Colombo, Eberhard Grube, Keith D. Dawkins, Mark Friedman, Donald S. Baim. (2008) Effect of Prolonged Thienopyridine Use After Drug-Eluting Stent Implantation (from the TAXUS Landmark Trials Data). The American Journal of Cardiology 102:8, 1017-1022
CrossRef394
Selcuk Dagdelen. (2008) Diabetic Cardiovascular Disease Lost in Translation Between Endocrinology and Cardiology. The American Journal of Cardiology 102:8, 1115-1116
CrossRef395
Sacco, Ralph L., Diener, Hans-Christoph, Yusuf, Salim, Cotton, Daniel, Ôunpuu, Stephanie, Lawton, William A., Palesch, Yuko, Martin, Reneé H., Albers, Gregory W., Bath, Philip, Bornstein, Natan, Chan, Bernard P.L., Chen, Sien-Tsong, Cunha, Luis, Dahlöf, Björn, De Keyser, Jacques, Donnan, Geoffrey A., Estol, Conrado, Gorelick, Philip, Gu, Vivian, Hermansson, Karin, Hilbrich, Lutz, Kaste, Markku, Lu, Chuanzhen, Machnig, Thomas, Pais, Prem, Roberts, Robin, Skvortsova, Veronika, Teal, Philip, Toni, Danilo, VanderMaelen, Cam, Voigt, Thor, Weber, Michael, Yoon, Byung-Woo, . (2008) Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. New England Journal of Medicine 359:12, 1238-1251
Full Text396
Emile Mohler, Jay Giri. (2008) Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. Current Medical Research and Opinion 24:9, 2509-2522
CrossRef397
José Biller. (2008) The role of antiplatelet therapy in the management of ischemic stroke: implementation of guidelines in current practice. Neurological Research 30:7, 669-677
CrossRef398
Peter D. Panagos. (2008) The approach to optimizing stroke care. The American Journal of Emergency Medicine 26:7, 808-816
CrossRef399
Mehdi H. Shishehbor, Sachin S. Goel, Samir R. Kapadia, Deepak L. Bhatt, Peter Kelly, Russell E. Raymond, John M. Galla, Sorin J. Brener, Patrick L. Whitlow, Stephen G. Ellis. (2008) Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality. Journal of the American College of Cardiology 52:13, 1041-1048
CrossRef400
Tobias Geisler, Elke Schaeffeler, Juergen Dippon, Stefan Winter, Verena Buse, Christian Bischofs, Christine Zuern, Klaus Moerike, Meinrad Gawaz, Matthias Schwab. (2008) CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9:9, 1251-1259
CrossRef401
B. Stratmann. (2008) Thrombozytenfunktion bei Diabetes mellitus. Der Diabetologe 4:6, 429-434
CrossRef402
Sasidhar Guthikonda, Carlos L. Alviar, Muthiah Vaduganathan, Mehmet Arikan, Armando Tellez, Timothy DeLao, Juan F. Granada, Jing-Fei Dong, Neal S. Kleiman, Eli I. Lev. (2008) Role of Reticulated Platelets and Platelet Size Heterogeneity on Platelet Activity After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology 52:9, 743-749
CrossRef403
Lisa T. Newsome, Michael A. Kutcher, Roger L. Royster. (2008) Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. Anesthesia & Analgesia 107:2, 552-569
CrossRef404
R. Sternitzky. (2008) Makroangiopathie bei Diabetes mellitus. Clinical Research in Cardiology Supplements 3:1, 29-34
CrossRef405
Dominick J. Angiolillo, Luis A. Guzman, Theodore A. Bass. (2008) Current antiplatelet therapies: Benefits and limitations. American Heart Journal 156:2, 3S-9S
CrossRef406
Brett Cucchiara, Michael Ross. (2008) Transient Ischemic Attack: Risk Stratification and Treatment. Annals of Emergency Medicine 52:2, S27-S39
CrossRef407
Mehmet Akif Duzenli, Kurtulus Ozdemir, Nazif Aygul, Ahmet Soylu, Mehmet Tokac. (2008) Comparison of Increased Aspirin Dose Versus Combined Aspirin Plus Clopidogrel Therapy in Patients With Diabetes Mellitus and Coronary Heart Disease and Impaired Antiplatelet Response to Low-Dose Aspirin. The American Journal of Cardiology 102:4, 396-400
CrossRef408
Norbert Zimmermann, Emmeran Gams, Thomas Hohlfeld. (2008) Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. European Journal of Cardio-Thoracic Surgery 34:1, 93-108
CrossRef409
Hyung-Hwan Kim, Naoki Sawada, Guray Soydan, Ho-Seong Lee, Zhipeng Zhou, Seo-Kyoung Hwang, Christian Waeber, Michael A Moskowitz, James K Liao. (2008) Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. Journal of Cerebral Blood Flow & Metabolism 28:7, 1285-1293
CrossRef410
David B. Sommer, Larry B. Goldstein. 2008. Central Nervous System (CNS). .
CrossRef411
Richard A. Bernstein. (2008) Antiplatelet agents for secondary prevention of stroke. Current Treatment Options in Cardiovascular Medicine 10:3, 223-228
CrossRef412
Victor L. Serebruany, Alex I. Malinin, James J. Ferguson, Javad Vahabi, Dan Atar, Charles H. Hennekens. (2008) Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129 314 patients. Fundamental & Clinical Pharmacology 22:3, 315-321
CrossRef413
Thomas Walter, Sebastian Szabo MD, Silke Kazmaier, Stefanie Swoboda, Tim Suselbeck, Martina Brueckmann MD, M Borggrefe, Martin E Beyer, Hans Martin Hoffmeister. (2008) Effect of Clopidogrel on Adhesion Molecules, Hemostasis, and Fibrinolysis in Coronary Heart Disease. Journal of Cardiovascular Pharmacology 51:6, 616-620
CrossRef414
Bryan P. Yan, Stephen J. Duffy, David J. Clark, Jeffery Lefkovits, Roderic Warren, Ronen Gurvitch, Robert Lew, Martin Sebastian, Angela Brennan, Nick Andrianopoulos, Christopher M. Reid, Andrew E. Ajani. (2008) Rates of Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents (from a Large Australian Multicenter Registry). The American Journal of Cardiology 101:12, 1716-1722
CrossRef415
D BHATT. (2008) Anti-Inflammatory Agents and Antioxidants as a Possible “Third Great Wave” in Cardiovascular Secondary Prevention. The American Journal of Cardiology 101:10, S4-S13
CrossRef416
P. Gresele, R. Migliacci. (2008) The peripheral arterial disease subgroup in the CHARISMA trial: does it tell us anything new?. European Heart Journal 30:2, 131-132
CrossRef417
P. P. Cacoub, D. L. Bhatt, P.G. Steg, E. J. Topol, M. A. Creager, . (2008) Patients with peripheral arterial disease in the CHARISMA trial. European Heart Journal 30:2, 192-201
CrossRef418
C. Denzel, W. Lang. (2008) Kritische Extremitätenischämie. Der Chirurg 79:5, 495-508
CrossRef419
Lina Badimon, Gemma Vilahur. (2008) Enfermedad aterotrombótica coronaria: avances en el tratamiento antiplaquetario. Revista Española de Cardiología 61:5, 501-513
CrossRef420
William M. Stone, Bart M. Demaerschalk, Richard J. Fowl, Samuel R. Money. (2008) Type 3 Phosphodiesterase Inhibitors May Be Protective Against Cerebrovascular Events in Patients with Claudication. Journal of Stroke and Cerebrovascular Diseases 17:3, 129-133
CrossRef421
Niteesh K. Choudhry, Raisa Levin, Jerry Avorn. (2008) The economic consequences of non–evidence-based clopidogrel use. American Heart Journal 155:5, 904-909
CrossRef422
Geoffrey A Donnan, Marc Fisher, Malcolm Macleod, Stephen M Davis. (2008) Stroke. The Lancet 371:9624, 1612-1623
CrossRef423
Thomas F. Rehring, Ryan S. Stolcpart, H. Whitton Hollis. (2008) Pharmacologic risk factor management in peripheral arterial disease: A vade mecum for vascular surgeons. Journal of Vascular Surgery 47:5, 1108-1115
CrossRef424
Bruce Ovbiagele. (2008) Antiplatelet Therapy in Management of Transient Ischemic Attack: Overview and Evidence-Based Rationale. The Journal of Emergency Medicine 34:4, 389-396
CrossRef425
Armen Yuri Gasparyan, Timothy Watson, Gregory Y.H. Lip. (2008) The Role of Aspirin in Cardiovascular Prevention. Journal of the American College of Cardiology 51:19, 1829-1843
CrossRef426
Deepak Thomas, Robert P Giugliano. (2008) Antiplatelet Therapy in Early Management of Non-ST-segment Elevation Acute Coronary Syndrome: The 2002 and 2007 Guidelines From North America and Europe. Journal of Cardiovascular Pharmacology 51:5, 425-433
CrossRef427
Stephen D. Wiviott, Eugene Braunwald, Sabina A. Murphy, Elliott M. Antman. (2008) A Perspective on the Efficacy and Safety of Intensive Antiplatelet Therapy in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38. The American Journal of Cardiology 101:9, 1367-1370
CrossRef428
Victor L. Serebruany. (2008) Excess Rates of Nonfatal Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel (Preventing Clinical Events or Chasing Enzymatic Ghosts?). The American Journal of Cardiology 101:9, 1364-1366
CrossRef429
(2008) Platelet Activation and Atherothrombosis. New England Journal of Medicine 358:15, 1638-1639
Full Text430
RON WAKSMAN, RAJBABU PAKALA, PROBAL ROY, RICHARD BAFFOUR, DAVID HELLINGA, RUFUS SEABRON, ROSANNA CHAN, MICKEY SCHEINOWITZ, FRANK KOLODGIE, RENU VIRMANI. (2008) Effect of Clopidogrel on Neointimal Formation and Inflammation in Balloon-Denuded and Radiated Hypercholesterolemic Rabbit Iliac Arteries. Journal of Interventional Cardiology 21:2, 122-128
CrossRef431
Jose G. Romano, Ralph L. Sacco. (2008) Progress in secondary stroke prevention. Annals of Neurology 63:4, 418-427
CrossRef432
J. Willeit, S. Kiechl, F. Aichner, K. Berek, H. Binder, M. Brainin, F. Fazekas, G. Fraedrich, H.P. Haring, S. Horner, B. Iglseder, P. Kapeller, W. Lang, E. Minar, K. Niederkorn, G. Noisternig, M. Schillinger, R. Schmidt, E. Schmutzhard, P. Waldenberger, H.W. Wege. (2008) Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13:2, 115-125
CrossRef433
Colin R. Simpson, Karen Alford, David Williams. (2008) Evidence for prolonged prescribing of aspirin–clopidogrel combination in Scottish primary care. Pharmacoepidemiology and Drug Safety 17:4, 397-400
CrossRef434
Christopher J. Lockhart, Paul K. Hamilton, Katherine A. McVeigh, Gary E. McVeigh. (2008) A cardiologist view of vascular disease in diabetes. Diabetes, Obesity and Metabolism 10:4, 279-292
CrossRef435
Patricia J.M. Best, Steven R. Steinhubl, Peter B. Berger, Arijit Dasgupta, Danielle M. Brennan, Lynda A. Szczech, Robert M. Califf, Eric J. Topol. (2008) The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. American Heart Journal 155:4, 687-693
CrossRef436
Ashna D.K. Bowry, M. Alan Brookhart, Niteesh K. Choudhry. (2008) Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular Events. The American Journal of Cardiology 101:7, 960-966
CrossRef437
Nick Sevdalis, Rosamond Jacklin. (2008) Interaction effects and subgroup analyses in clinical trials: more than meets the eye?. Journal of Evaluation in Clinical Practice 0:0, 080326234500857-???
CrossRef438
Eugene Braunwald, Dominick Angiolillo, Eric Bates, Peter B. Berger, Deepak Bhatt, Christopher P. Cannon, Mark I. Furman, Paul Gurbel, Alan D. Michelson, Eric Peterson, Stephen Wiviott. (2008) Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. Clinical Cardiology 31:S1, I28-I35
CrossRef439
Yung-Wei Chi, Michael R. Jaff. (2008) Optimal risk factor modification and medical management of the patient with peripheral arterial disease. Catheterization and Cardiovascular Interventions 71:4, 475-489
CrossRef440
Steven B. Deitelzweig, James W. Hoekstra. (2008) Peripheral arterial disease and the hospitalist: The rationale for early detection and optimal therapy. Journal of Hospital Medicine 3:S2, S4-S8
CrossRef441
Eugene Braunwald, Dominick Angiolillo, Eric Bates, Peter B. Berger, Deepak Bhatt, Christopher P. Cannon, Mark I. Furman, Paul Gurbel, Alan D. Michelson, Eric Peterson, Stephen Wiviott. (2008) Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes. Clinical Cardiology 31:S1, I2-I9
CrossRef442
Marc Fisher, Edward Folland. (2008) Acute Ischemic Coronary Artery Disease and Ischemic Stroke: Similarities and Differences. American Journal of Therapeutics 15:2, 137-149
CrossRef443
David P. Taggart, Sanjay Kaul, William E. Boden, T. Bruce Ferguson, Robert A. Guyton, Michael J. Mack, Paul T. Sergeant, Richard J. Shemin, Peter K. Smith, Salim Yusuf. (2008) Revascularization for Unprotected Left Main Stem Coronary Artery Stenosis. Journal of the American College of Cardiology 51:9, 885-892
CrossRef444
J George, M Fisher, G McKay. (2008) Clopidogrel. Practical Diabetes International 25:2, 80-81
CrossRef445
Geoffrey S. F. Ling. (2008) Aggressive management of ischemic stroke: The case for the hospitalist. Journal of Hospital Medicine 3:S2, S9-S14
CrossRef446
Samer Ellahham. (2008) Role of Antiplatelet Agents in the Primary and Secondary Prevention of Atherothrombotic Events in High Risk-Patients. Southern Medical Journal 101:3, 273-283
CrossRef447
E. Marc Jolicoeur, Christopher B. Granger, Timothy D. Henry, David J. Holmes, Carl J. Pepine, Daniel Mark, Bernard R. Chaitman, Bernard J. Gersh, E. Magnus Ohman. (2008) Clinical and research issues regarding chronic advanced coronary artery disease. American Heart Journal 155:3, 418-434
CrossRef448
David Faxon, Marie Brown. (2008) Antiplatelet Therapy for Postdischarge Medical Management of Acute Coronary Syndrome. The American Journal of Medicine 121:3, 171-178
CrossRef449
M. Cattaneo. (2008) Haemorrhagic stroke during anti-platelet therapy. European Journal of Anaesthesiology 25:Supplement 42, 12-15
CrossRef450
J. Willeit, S. Kiechl, F. Aichner, K. Berek, H. Binder, M. Brainin, F. Fazekas, G. Fraedrich, H.P. Haring, S. Horner, B. Iglseder, P. Kapeller, W. Lang, E. Minar, K. Niederkorn, G. Noisternig, M. Schillinger, R. Schmidt, E. Schmutzhard, P. Waldenberger, H.W. Wege. (2008) Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13:1, 31-41
CrossRef451
Martin K. Stiles, Omar H. Dabbous, Keith A.A. Fox. (2008) Bleeding Events with Antithrombotic Therapy in Patients with Unstable Angina or non-ST-segment Elevation Myocardial Infarction; Insights from a Large Clinical Practice Registry (GRACE). Heart, Lung and Circulation 17:1, 5-8
CrossRef452
Mark J. Alberts. (2008) CHARISMA revisited: is the glass half full or just empty?. International Journal of Stroke 3:1, 16-19
CrossRef453
Ramez R Fares, Lawrence S Lansing, Christine A Gallati, Shaker A Mousa. (2008) Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. Expert Opinion on Pharmacotherapy 9:3, 377-386
CrossRef454
Shelagh B. Coutts, Michael Eliasziw, Michael D. Hill, James N. Scott, Suresh Subramaniam, Alastair M. Buchan, Andrew M. Demchuk, . (2008) An improved scoring system for identifying patients at high early risk of stroke and functional impairment after an acute transient ischemic attack or minor stroke. International Journal of Stroke 3:1, 3-10
CrossRef455
Ascan Warnholtz, Mir Abolfazl Ostad, Nathalie Velich, Christine Trautmann, Reinhard Schinzel, Ulrich Walter, Thomas Munzel. (2008) A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double-blind, randomized study. Atherosclerosis 196:2, 689-695
CrossRef456
Susan C. Fagan. (2008) Urgent Need for Secondary Stroke Prevention After Transient Ischemic Attack. The Consultant Pharmacist 23:2, 131-140
CrossRef457
David J. Likosky, Kiwon Lee, David M. Brown, Alpesh Amin, Daniel David Dressler, David Krakow, Saad Rahman, Dara G. Jamieson. (2008) Evidence-based medicine: Review of guidelines and trials in the prevention of secondary stroke. Journal of Hospital Medicine 3:S4, S6-S19
CrossRef458
Cathy M. Helgason, Enzo Grossi, Dilip Pandey, Aziz Valika, John Cursio, Larry D. Brace. (2008) Platelet Aggregation and Recruitment with Aspirin-Clopidogrel Therapy. Cerebrovascular Diseases 25:5, 392-400
CrossRef459
Robert A. Phillips. (2008) A Review of Therapeutic Strategies for Risk Reduction of Recurrent Stroke. Progress in Cardiovascular Diseases 50:4, 264-273
CrossRef460
Tsukasa OHMORI. (2008) Anti-platelet treatment for acute coronary syndrome in Japan. Japanese Journal of Thrombosis and Hemostasis 19:4, 504-509
CrossRef461
Robert G. Hart, Deepak L. Bhatt, Werner Hacke, Keith A.A. Fox, Graeme J. Hankey, Peter B. Berger, Tingfei Hu, Eric J. Topol. (2008) Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Stroke in Patients with a History of Atrial Fibrillation: Subgroup Analysis of the CHARISMA Randomized Trial. Cerebrovascular Diseases 25:4, 344-347
CrossRef462
Elliott M. Antman, Mary Hand, Paul W. Armstrong, Eric R. Bates, Lee A. Green, Lakshmi K. Halasyamani, Judith S. Hochman, Harlan M. Krumholz, Gervasio A. Lamas, Charles J. Mullany, David L. Pearle, Michael A. Sloan, Sidney C. Smith. (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 51:2, 210-247
CrossRef463
D. Adam Lauver, Edward M. Driscoll, Benedict R. Lucchesi. (2008) Disodium Disuccinate Astaxanthin Prevents Carotid Artery Rethrombosis and ex vivo Platelet Activation. Pharmacology 82:1, 67-73
CrossRef464
(2008) 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 71:1, E1-E40
CrossRef465
Neil E. Schwartz, Gregory W. Albers. (2008) Use of antiplatelet agents to prevent stroke: What is the role for combinations of medications?. Current Neurology and Neuroscience Reports 8:1, 29-34
CrossRef466
Young Il Jeon, Do Hoon Kwon. (2008) Current Status and Future Prospect of Endovascular Neurosurgery. Journal of Korean Neurosurgical Society 43:2, 69
CrossRef467
Matthias W Riepe, Roman Huber. (2008) Secondary Stroke Prevention. CNS Drugs 22:2, 113-121
CrossRef468
(2008) Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovascular Diseases 25:5, 457-507
CrossRef469
Cindy Grines, Leslie Cho. (2008) Atherothrombotic Disease and the Role of Antiplatelet Therapy in Women. Journal of Women's Health 17:1, 35-46
CrossRef470
S. L. Spinelli, J. J. O'Brien, S. Bancos, G. M. Lehmann, D. L. Springer, N. Blumberg, C. W. Francis, M. B. Taubman, R. P. Phipps. (2008) The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. PPAR Research 2008, 1-16
CrossRef471
Guillaume Cayla, Jean Christophe Macia, François Roubille, Herisoa Rabesendratana, Christophe Piot, Jean François Schved, Florence Leclercq. (2008) Repeated High Doses of Clopidogrel in 2 Cases of Pharmacological Resistance. Circulation Journal 72:12, 2098-2100
CrossRef472
Maryna Skliut, Dara G. Jamieson. (2008) Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT. Current Cardiology Reports 10:1, 9-16
CrossRef473
Jesse Weinberger. (2008) Antiplatelet Agents for Stroke Prevention Following Transient Ischemic Attack. Southern Medical Journal 101:1, 70-78
CrossRef474
Spencer B. King, Sidney C. Smith, John W. Hirshfeld, Alice K. Jacobs, Douglass A. Morrison, David O. Williams. (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:2, 172-209
CrossRef475
Jill S. Burkiewicz, Kimi S. Vesta, Anne L. Hume. (2008) Improving Effectiveness in Communicating Risk to Patients. The Consultant Pharmacist 23:1, 37-43
CrossRef476
Philip B. Gorelick. (2008) Antiplatelet therapy for recurrent stroke prevention: newer perspectives based on (MATCH), (CHARISMA), and (ESPRIT). Journal of the American Society of Hypertension 2:1, 3-7
CrossRef477
Kiwon Lee, David M. Brown, Daniel David Dressler, Alpesh Amin, Dara G. Jamieson, David Krakow, Saad Rahman, David J. Likosky. (2008) Secondary prevention of ischemic stroke: Challenging patient scenarios. Journal of Hospital Medicine 3:S4, S20-S28
CrossRef478
S. Achterberg, L.J. Kappelle, A. Algra. (2008) Prognostic Modelling in Ischaemic Stroke Study, Additional Value of Genetic Characteristics. European Neurology 59:5, 243-252
CrossRef479
Norio Tanahashi. (2008) Antiplatelet agents for ischemic stroke: current status and future directions. Nosotchu 30:6, 834-840
CrossRef480
Prakash Deedwania, Sundararajan Srikanth. (2008) Diabetes and vascular disease. Expert Review of Cardiovascular Therapy 6:1, 127-138
CrossRef481
Madhu Chintala, Kenji Shimizu, Masami Ogawa, Hiroya Yamaguchi, Masaki Doi, Peder Jensen. (2008) Basic and Translational Research on Proteinase-Activated Receptors: Antagonism of the Proteinase-Activated Receptor 1 for Thrombin, a Novel Approach to Antiplatelet Therapy for Atherothrombotic Disease. Journal of Pharmacological Sciences 108:4, 433-438
CrossRef482
T. GEISLER, D. GRAß, B. BIGALKE, K. STELLOS, T. DROSCH, K. DIETZ, C. HERDEG, M. GAWAZ. (2008) The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. Journal of Thrombosis and Haemostasis 6:1, 54-61
CrossRef483
Mark L. De Buyzere, Denis L. Clement. (2008) Management of Hypertension in Peripheral Arterial Disease. Progress in Cardiovascular Diseases 50:4, 238-263
CrossRef484
Samir Saha, Margareta Berglund, Christer Sylvén, Allan Gordon, Stefan Agewall. (2008) Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. International Journal of Cardiology 123:2, 195-196
CrossRef485
William E. Braun. 2008. Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. , 1009-1033.
CrossRef486
Sean Ruland. (2008) Safety of Clopidogrel and Aspirin for??Stroke Prevention. Drug Safety 31:6, 449-458
CrossRef487
Hideki Origasa, Shinya Goto, Shinichiro Uchiyama, Kazuyuki Shimada, Yasuo Ikeda, The J-TRACE Investigators. (2008) The Japan Thrombosis Registry for Atrial Fibrillation, Coronary or Cerebrovascular Events (J-TRACE). Circulation Journal 72:6, 991-997
CrossRef488
A.A. Rabinstein. (2008) Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Yearbook of Neurology and Neurosurgery 2008, 36-38
CrossRef489
G.L. Moneta. (2008) Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. Yearbook of Vascular Surgery 2008, 55-57
CrossRef490
José Biller, Betsy B. Love, Michael J. Schneck. 2008. Vascular Diseases of the Nervous System. , 1165-1223.
CrossRef491
Xavier Armoiry, Xavier Dode, Éric Bonnefoy, Gilles Aulagner, François Gimenez†, Éric François. 2008. Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. , 127-155.
CrossRef492
Davì, Giovanni, Patrono, Carlo, . (2007) Platelet Activation and Atherothrombosis. New England Journal of Medicine 357:24, 2482-2494
Full Text493
Bryan P. Yan, Ronen Gurvitch, Stephen J. Duffy, David J. Clark, Martin Sebastian, Gishel New, Roderick Warren, Jeffery Lefkovits, Robert Lew, Angela L. Brennan, Chris Reid, Nick Andrianopoulos, Andrew E. Ajani. (2007) An evaluation of octogenarians undergoing percutaneous coronary intervention from the Melbourne Interventional Group registry. Catheterization and Cardiovascular Interventions 70:7, 928-936
CrossRef494
M. Cohen, G. Roubin, F. Kuepper. (2007) The challenge of ST-segment elevation myocardial infarction. International Journal of Clinical Practice 61:12, 2079-2092
CrossRef495
JEFFREY J. POPMA, BONNIE WEINER, MICHAEL J. COWLEY, CHARLES SIMONTON, DAN McCORMICK, TED FELDMAN. (2007) FDA Advisory Panel on the Safety and Efficacy of Drug-Eluting Stents: Summary of Findings and Recommendations. Journal of Interventional Cardiology 20:6, 425-446
CrossRef496
Dan James Fintel. (2007) Antiplatelet Therapy in Cerebrovascular Disease: Implications of MATCH and CHARISMA Results for Cardiologists. Clinical Cardiology 30:12, 604-614
CrossRef497
Toby C Trujillo, Paul P Dobesh. (2007) Traditional Management of Chronic Stable Angina. Pharmacotherapy 27:12, 1677-1692
CrossRef498
Bhatt, Deepak L., . (2007) Intensifying Platelet Inhibition — Navigating between Scylla and Charybdis. New England Journal of Medicine 357:20, 2078-2081
Full Text499
Gord Gubitz. 2007. Acute Stroke Manatement and Prevention of Recurrences. , 113-126.
CrossRef500
S Claiborne Johnston. (2007) Towards FASTER treatment of TIA and minor stroke. The Lancet Neurology 6:11, 941-943
CrossRef501
Girish R. Mood, Deepak L. Bhatt. (2007) Clopidogrel and risk for acute coronary events. Current Atherosclerosis Reports 9:5, 401-408
CrossRef502
James Kennedy, Michael D Hill, Karla J Ryckborst, Michael Eliasziw, Andrew M Demchuk, Alastair M Buchan. (2007) Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. The Lancet Neurology 6:11, 961-969
CrossRef503
Pallav Garg, Laura Mauri. (2007) The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. Current Opinion in Cardiology 22:6, 565-571
CrossRef504
Jeffrey A. Switzer, David C. Hess. (2007) Carotid stenosis: Endarterectomy or angioplasty and stenting?. Current Treatment Options in Neurology 9:6, 451-462
CrossRef505
Neil E. Schwartz, Gregory W. Albers. (2007) Is there a role for combinations of antiplatelet agents in stroke prevention?. Current Treatment Options in Neurology 9:6, 442-450
CrossRef506
Freek WA Verheugt. (2007) How can the bleeding risk associated with warfarin therapy be reduced?. Nature Clinical Practice Cardiovascular Medicine
CrossRef507
H. S. Kirshner. (2007) Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician role. International Journal of Clinical Practice 61:10, 1739-1748
CrossRef508
Sheryl Martin-Schild, James C Grotta. (2007) Future of stroke treatment. Aging Health 3:5, 595-600
CrossRef509
John M Galla, A Michael Lincoff. (2007) The role of clopidogrel in the management of ischemic heart disease. Current Opinion in Internal Medicine 6:5, 454-460
CrossRef510
James M. Gebel. (2007) The CAPRIE-Like Subgroups of CHARISMA: A CAPRIEciously Biased Analysis of an unCHARISMAtic Truth. Journal of the American College of Cardiology 50:17, 1704
CrossRef511
Deepak L. Bhatt, Marcus D. Flather. (2007) Reply. Journal of the American College of Cardiology 50:17, 1704-1705
CrossRef512
(2007) Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Española de Cardiología 60:10, 1070.e1-1070.e80
CrossRef513
Nauder Faraday, Diane M Becker, Lewis C Becker. (2007) Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics 8:10, 1413-1425
CrossRef514
M. J. Alberts, B. Ovbiagele. (2007) Current strategies for ischemic stroke prevention: role of multimodal combination therapies. Journal of Neurology 254:10, 1414-1426
CrossRef515
Dara G. Jamieson. (2007) Secondary Prevention of Ischemic Stroke: Evolution from a Stepwise to a Risk Stratification Approach to Care. Disease Management 10:5, 273-284
CrossRef516
R. Weber, H.C. Diener, M. Grond. (2007) Aktuelle Aspekte der Sekundärprophylaxe des ischämischen Schlaganfalls. Der Nervenarzt 78:10, 1138-1146
CrossRef517
D. Scheinert, A. Schmidt. (2007) Karotisstenose. Der Kardiologe 1:3, 217-228
CrossRef518
Charles M Mather, Kathryn M King, Pam LeBlanc. (2007) Meanings of the heart among a group of older Sikh immigrant women with cardiovascular disease. International Journal of Multiple Research Approaches 1:1, 39-51
CrossRef519
Giuseppe Curigliano, Alessandra Balduzzi, Anna Cardillo, Raffaella Ghisini, Giulia Peruzzotti, Laura Orlando, Rosalba Torrisi, Silvia Dellapasqua, Loredana Lunghi, Aron Goldhirsch, Marco Colleoni. (2007) Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. Supportive Care in Cancer 15:10, 1213-1217
CrossRef520
Gregory Ducrocq, Victor Serebruany, Jean-Francois Tanguay. (2007) Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. Expert Review of Cardiovascular Therapy 5:5, 939-953
CrossRef521
William M. Landau. (2007) Pertinacious prescription of practice paradigms: The ethical burden of coercive clinical guidelines. Current Neurology and Neuroscience Reports 7:5, 355-358
CrossRef522
Hans-Christoph Diener. (2007) The PRoFESS trial: future impact on secondary stroke prevention. Expert Review of Neurotherapeutics 7:9, 1085-1091
CrossRef523
Victor L. Serebruany. (2007) The “Clopidogrel Resistance” Trap. The American Journal of Cardiology 100:6, 1044-1046
CrossRef524
Pavel P. Osmancik, Frantisek Bednar, Heidi Móciková. (2007) Glycemia, triglycerides and disease severity are best associated with higher platelet activity in patients with stable coronary artery disease. Journal of Thrombosis and Thrombolysis 24:2, 105-107
CrossRef525
Nitin Purandare, Richard C. Oude Voshaar, Julie Morris, Jane E. Byrne, Joanne Wren, Richard F. Heller, Charles N. McCollum, Alistair Burns. (2007) Asymptomatic Spontaneous Cerebral Emboli Predict Cognitive and Functional Decline in Dementia. Biological Psychiatry 62:4, 339-344
CrossRef526
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef527
Justin R Hamilton, Zane Kaplan, Shaun P Jackson, Stephen Opat. (2007) Antiplatelet therapy: present status and future prospects. Expert Opinion on Drug Discovery 2:8, 1035-1040
CrossRef528
Keith AA Fox, Raj Chelliah. (2007) Clopidogrel: an updated and comprehensive review. Expert Opinion on Drug Metabolism & Toxicology 3:4, 621-631
CrossRef529
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliot M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 50:7, 652-726
CrossRef530
Darya Malinina, Carla Zema, Stephen Sander, Victor Serebruany. (2007) Cost–effectiveness of antiplatelet therapy for secondary stroke prevention. Expert Review of Pharmacoeconomics & Outcomes Research 7:4, 357-363
CrossRef531
(2007) PCI for Stable Coronary Disease. New England Journal of Medicine 357:4, 414-418
Full Text532
Alessandro Squizzato, Tymen Keller, Saskia Middeldorp, Alessandro Squizzato. 2007. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. .
CrossRef533
Maria I Aguilar, Robert Hart, Lesly A Pearce, Maria I Aguilar. 2007. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. .
CrossRef534
M. CATTANEO. (2007) Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. Journal of Thrombosis and Haemostasis 5, 230-237
CrossRef535
Jacqueline Saw, Danielle M. Brennan, Steven R. Steinhubl, Deepak L. Bhatt, Koon-Hou Mak, Keith Fox, Eric J. Topol. (2007) Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial. Journal of the American College of Cardiology 50:4, 291-295
CrossRef536
Victor L Serebruany, Alex Malinin, Christian Eisert, Stephen Ong. (2007) AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis. Expert Review of Cardiovascular Therapy 5:4, 635-641
CrossRef537
Mallik R. Thatipelli, Patricia A. Pellikka, Robert D. McBane, Thom W. Rooke, Gabriela A. Rosales, David Hodge, Regina M. Herges, Waldemar E. Wysokinski. (2007) Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. Journal of Vascular Surgery 46:1, 62-70
CrossRef538
Graeme J. Hankey. (2007) Antiplatelet therapy for stroke prevention. Current Atherosclerosis Reports 9:4, 312-318
CrossRef539
Dominick J. Angiolillo, Fernando Alfonso. (2007) Clopidogrel–Statin Interaction. Journal of the American College of Cardiology 50:4, 296-298
CrossRef540
Denis L. Clement, Marc L. Debuyzere. (2007) How to treat hypertension in patients with peripheral artery disease. Current Hypertension Reports 9:3, 190-195
CrossRef541
P. Fontana, J.-L. Reny. (2007) New Antiplatelet Strategies in Atherothrombosis and Their Indications. European Journal of Vascular and Endovascular Surgery 34:1, 10-17
CrossRef542
Sahil A. Parikh, Joshua A. Beckman. (2007) Contemporary use of clopidogrel in patients with coronary artery disease. Current Cardiology Reports 9:4, 257-263
CrossRef543
Sanjay Kaul, Prediman K. Shah, George A. Diamond. (2007) As Time Goes By. Journal of the American College of Cardiology 50:2, 128-137
CrossRef544
Daniel A Duprez. (2007) Pharmacological interventions for peripheral artery disease. Expert Opinion on Pharmacotherapy 8:10, 1465-1477
CrossRef545
R. Sternitzky, S. Sternitzky. (2007) Kardio- und zerebrovaskuläres Risiko bei PAVK. Clinical Research in Cardiology Supplements 2:4, IV22-IV29
CrossRef546
Stephen E. Van Horn, Calin V. Maniu. (2007) Management of non–ST-Segment Elevation Myocardial Infarction. Medical Clinics of North America 91:4, 683-700
CrossRef547
Lisa Senzel, Dmitri V Gnatenko, Wadie F Bahou. (2007) Platelet transcriptome and cardiovascular disease. Future Cardiology 3:4, 391-398
CrossRef548
Afshin Assadian, Jaqueline Lax, Ursula Meixner-Loicht, Georg W. Hagmüller, Peter Michael Bayer, Wolfgang Hübl. (2007) Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: Flow cytometric measurement of aspirin-induced platelet inhibition. Journal of Vascular Surgery 45:6, 1142-1147
CrossRef549
M. Troxler, K. Dickinson, S. Homer-Vanniasinkam. (2007) Platelet function and antiplatelet therapy. British Journal of Surgery 94:6, 674-682
CrossRef550
Graeme J. Hankey. (2007) Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. Current Medical Research and Opinion 23:6, 1453-1462
CrossRef551
Sanjay Kaul, George A. Diamond. (2007) Current Status and Future Trends in Drug-Eluting Stents. The American Heart Hospital Journal 5:3, 165-168
CrossRef552
Pierre-Guy Chassot, Alain Delabays, Donat R. Spahn. (2007) Perioperative use of anti-platelet drugs. Best Practice & Research Clinical Anaesthesiology 21:2, 241-256
CrossRef553
L. Lorgis, M. Zeller, J.-C. Beer, P. Buffet, I. L'Huillier, C. Nguyen, F. Schaad, P. Obbee, A.-C. Lagrost, Y. Cottin. (2007) Prise en charge au long cours par les anti-agrégants plaquettaires oraux après un syndrome coronaire aigu. Annales de Cardiologie et d'Angéiologie 56, S29-S35
CrossRef554
Luca Testa, Giuseppe Biondi Zoccai, Italo Porto, Graziana Trotta, Pierfrancesco Agostoni, Felicita Andreotti, Filippo Crea. (2007) Adjusted Indirect Meta-Analysis of Aspirin Plus Warfarin at International Normalized Ratios 2 to 3 Versus Aspirin Plus Clopidogrel After Acute Coronary Syndromes. The American Journal of Cardiology 99:12, 1637-1642
CrossRef555
(2007) Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Española de Cardiología 60:5, 525.e1-525.e64
CrossRef556
Deepak L. Bhatt, Marcus D. Flather, Werner Hacke, Peter B. Berger, Henry R. Black, William E. Boden, Patrice Cacoub, Eric A. Cohen, Mark A. Creager, J. Donald Easton, Christian W. Hamm, Graeme J. Hankey, S. Claiborne Johnston, Koon-Hou Mak, Jean-Louis Mas, Gilles Montalescot, Thomas A. Pearson, P. Gabriel Steg, Steven R. Steinhubl, Michael A. Weber, Liz Fabry-Ribaudo, Tingfei Hu, Eric J. Topol, Keith A.A. Fox. (2007) Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology 49:19, 1982-1988
CrossRef557
Marten Otten. (2007) Maagbescherming bij vaatbescherming?. Huisarts en Wetenschap 50:5, 348-353
CrossRef558
G. E. Kikano, M. T. Brown. (2007) Antiplatelet Therapy for Atherothrombotic Disease: An Update for the Primary Care Physician. Mayo Clinic Proceedings 82:5, 583-593
CrossRef559
S. Khan, M. Flather, R. Mister, N. Delahunty, G. Fowkes, A. Bradbury, G. Stansby. (2007) Characteristics and Treatments of Patients with Peripheral Arterial Disease Referred to UK Vascular Clinics: Results of a Prospective Registry. European Journal of Vascular and Endovascular Surgery 33:4, 442-450
CrossRef560
Jessica Carpenter, Tammy Tsuchida, John Kylan Lynch. (2007) Treatment of arterial ischemic stroke in children. Expert Review of Neurotherapeutics 7:4, 383-392
CrossRef561
Kristi L Emmons, Nicole R Taylor. (2007) Contemporary Issues in Clopidogrel Therapy: New Evidence Shaping Clinical Practice. Pharmacotherapy 27:4, 553-563
CrossRef562
Dominick J Angiolillo. (2007) Antiplatelet therapy in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity 14:2, 124-131
CrossRef563
Graeme J Hankey. (2007) Clinical update: management of stroke. The Lancet 369:9570, 1330-1332
CrossRef564
Nicolas W Shammas. (2007) Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vascular Health and Risk Management 3:2, 229-234
CrossRef565
Hussam Hamdalla, Steven R. Steinhubl. (2007) Oral antiplatelet therapy for percutaneous coronary revascularization. Catheterization and Cardiovascular Interventions 69:5, 637-642
CrossRef566
Jessica N Redgrave, Peter M Rothwell. (2007) Asymptomatic carotid stenosis: what to do. Current Opinion in Internal Medicine 6:2, 156-162
CrossRef567
Javier Sanz, Pedro R. Moreno, Valentin Fuster. (2007) The Year in Atherothrombosis. Journal of the American College of Cardiology 49:16, 1740-1749
CrossRef568
George Howard, Leslie A McClure, John W Krakauer, Christopher S Coffey. (2007) Stroke and the statistics of the aspirin/clopidogrel secondary prevention trials. Current Opinion in Internal Medicine 6:2, 171-177
CrossRef569
H.-J. Wagner, M. El-Sheik. (2007) Indikation und Technik der kruralen PTA. Gefässchirurgie 12:2, 104-114
CrossRef570
Sheldon Greenfield, Richard Kravitz, Naihua Duan, Sherrie H. Kaplan. (2007) Heterogeneity of Treatment Effects: Implications for Guidelines, Payment, and Quality Assessment. The American Journal of Medicine 120:4, S3-S9
CrossRef571
G FLETCHER, V BUFALINO, F COSTA, L GOLDSTEIN, D JONES, L SMAHA, S SMITHJR, N STONE. (2007) Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. The American Journal of Cardiology 99:6, S1-S35
CrossRef572
R. Zambahari, O-H Kwok, S. Javier, K. H. Mak, S. Piyamitr, H. Q. Tri Ho, J. J. Hwang, R. Suryawan, W. H. Chow. (2007) Clinical use of clopidogrel in acute coronary syndrome. International Journal of Clinical Practice 61:3, 473-481
CrossRef573
A. Blinc, P. Poredoš. (2007) Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. European Journal of Clinical Investigation 37:3, 157-164
CrossRef574
Ramiro López Menchaca, Juan María Herrero Martínez, Carmen Suárez Fernández. (2007) Asociación de antiagregantes, ¿cuándo y cómo?. Medicina Clínica 128:10, 383-389
CrossRef575
M. CATTANEO, A. LECCHI. (2007) Inhibition of the platelet P2Y 12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. Journal of Thrombosis and Haemostasis 5:3, 577-582
CrossRef576
Norra MacReady. (2007) James C. Grotta. Neurology Today 7:6, 28-29
CrossRef577
Nabil N. Dagher, J. Gregory Modrall. (2007) Pharmacotherapy Before and After Revascularization: Anticoagulation, Antiplatelet Agents, and Statins. Seminars in Vascular Surgery 20:1, 10-14
CrossRef578
Victor L. Serebruany, Alex I. Malinin, Dan Atar, Dan F. Hanley. (2007) Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. American Heart Journal 153:3, 371-377
CrossRef579
Philip B. Gorelick. (2007) Life after ESPRIT: which first-line antiplatelet treatment should we use?. International Journal of Stroke 2:1, 40-42
CrossRef580
Javier Sanz, Pedro R Moreno, Valentin Fuster. (2007) Update on advances in atherothrombosis. Nature Clinical Practice Cardiovascular Medicine 4:2, 78-89
CrossRef581
Jesse Weinberger. (2007) Clinical trials report. Current Cardiology Reports 9:1, 5-6
CrossRef582
André J. Scheen, Delphine Legrand. (2007) Platelet Dysfunction Associated With Insulin Therapy in Patients With Type 2 Diabetes: Please Do Not Throw the Baby Out With the Bathwater!. Journal of the American College of Cardiology 49:5, 628
CrossRef583
W.H. Frishman. (2007) Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. Yearbook of Medicine 2007, 321-323
CrossRef584
Sergio Coccheri. (2007) Approaches to Prevention of Cardiovascular Complications and Events in Diabetes Mellitus. Drugs 67:7, 997-1026
CrossRef585
Xavier García-Moll, Alfredo Bardají, Joaquín Alonso, Héctor Bueno. (2007) Actualización en cardiopatía isquémica 2006. Revista Española de Cardiología 60, 3-18
CrossRef586
Hans-Christoph Diener, Ralph Sacco, Salim Yusuf. (2007) Rationale, Design and Baseline Data of a Randomized, Double-Blind, Controlled Trial Comparing Two Antithrombotic Regimens (a Fixed-Dose Combination of Extended-Release Dipyridamol plus ASS with Clopidogrel) and Telmisartan versus Placebo in Patients with Strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases 23:5-6, 368-380
CrossRef587
L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, F.G.R. Fowkes. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery 45:1, S5-S67
CrossRef588
PATRICIA O'MALLEY. (2007) Aspirin and Plavix. Clinical Nurse Specialist 21:1, 13-15
CrossRef589
A. Sokic-Milutinovic, M.N. Krstic, D. Popovic, N.S. Mijalkovic, S. Djuranovic, Dj. Culafic. (2007) Role of Helicobacter pylori infection and use of NSAIDs in the etiopathogenesis of upper gastrointestinal bleeding. Acta chirurgica iugoslavica 54:1, 51-62
CrossRef590
(2007) Invited Synopses. Acute Cardiac Care 9:3, 134-174
CrossRef591
L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, F.G.R. Fowkes. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular Surgery 33:1, S1-S75
CrossRef592
Thomas J Helton, Anthony A Bavry, Dharam J Kumbhani, Sandeep Duggal, Henri Roukoz, Deepak L Bhatt. (2007) Incremental Effect of Clopidogrel on Important??Outcomes in Patients with Cardiovascular Disease. American Journal of Cardiovascular Drugs 7:4, 289-297
CrossRef593
Jamie J. O’Brien, Denise M. Ray, Sherry L. Spinelli, Neil Blumberg, Mark B. Taubman, Charles W. Francis, Steven D. Wittlin, Richard P. Phipps. (2007) The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARγ ligands. Prostaglandins & Other Lipid Mediators 82:1-4, 68-76
CrossRef594
Dominick J Angiolillo. (2007) ADP Receptor Antagonism. American Journal of Cardiovascular Drugs 7:6, 423-432
CrossRef595
Zenon S Kyriakides, Spyros Kourouklis, Konstantinos Kontaras. (2007) Acute Coronary Syndromes in the Elderly. Drugs & Aging 24:11, 901-912
CrossRef596
Huyen A. Tran, Sonia S. Anand, Graeme J. Hankey, John W. Eikelboom. (2007) Aspirin resistance. Thrombosis Research 120:3, 337-346
CrossRef597
William E. Boden, Robert A. O’Rourke, Koon K. Teo, Pamela M. Hartigan, David J. Maron, William Kostuk, Merril Knudtson, Marcin Dada, Paul Casperson, Crystal L. Harris, John A. Spertus, Leslee Shaw, Bernard R. Chaitman, G.B. John Mancini, Daniel S. Berman, Gerald Gau, William S. Weintraub. (2007) The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial. The American Journal of Cardiology 99:2, 208-212
CrossRef598
Joachim Röther. (2007) Usefulness of Antiplatelet Drugs in Ischaemic Stroke Prevention – Update on New Trials. Cerebrovascular Diseases 24:1, 112-115
CrossRef599
Paul A. Gurbel, Udaya S. Tantry. (2007) Clopidogrel resistance?. Thrombosis Research 120:3, 311-321
CrossRef600
W.H. Frishman. (2007) Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. Yearbook of Medicine 2007, 331-334
CrossRef601
Eric R. Bates, Joseph D. Babb, Donald E. Casey, Christopher U. Cates, Gary R. Duckwiler, Ted E. Feldman, William A. Gray, Kenneth Ouriel, Eric D. Peterson, Kenneth Rosenfield, John H. Rundback, Robert D. Safian, Michael A. Sloan, Christopher J. White, Robert A. Harrington, Jonathan Abrams, Jeffrey L. Anderson, Eric R. Bates, Mark J. Eisenberg, Cindy L. Grines, Mark A. Hlatky, Robert C. Lichtenberg, Jonathan R. Lindner, Gerald M. Pohost, Richard S. Schofield, Samuel J. Shubrooks, James H. Stein, Cynthia M. Tracy, Robert A. Vogel, Deborah J. Wesley. (2007) ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting. Journal of the American College of Cardiology 49:1, 126-170
CrossRef602
Bruce Ovbiagele, Sandeep Sachdeva. (2007) Preventing another event: Role of the hospitalist in discharge stroke prevention. Journal of Hospital Medicine 2:1, 31-38
CrossRef603
P.H.A. Halkes, A. Algra. (2007) Anticoagulants, Aspirin and Dipyridamole in the Secondary Prevention of Cerebral Ischaemia: Which Is the Best for Which Patient?. Cerebrovascular Diseases 24:1, 107-111
CrossRef604
Greg L Plosker, Katherine A Lyseng-Williamson. (2007) Clopidogrel. Drugs 67:4, 613-646
CrossRef605
Marco Cattaneo. (2007) Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Review of Cardiovascular Therapy 5:1, 45-55
CrossRef606
B.J. Gersh. (2007) Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. Yearbook of Cardiology 2007, 271-273
CrossRef607
Victor L. Serebruany, Dan Atar. (2007) Assessment of Bleeding Events in Clinical Trials—Proposal of a New Classification. The American Journal of Cardiology 99:2, 288-290
CrossRef608
Padmavathy N Sylaja, Michael D Hill. (2007) Current Management of Transient Ischemic Attack. American Journal of Cardiovascular Drugs 7:1, 67-74
CrossRef609
Jaime Gállego, Eduardo Martínez Vila, Roberto Muñoz. (2007) Patients at High Risk for Ischemic Stroke: Identification and Actions. Cerebrovascular Diseases 24:1, 49-63
CrossRef610
EDMOND W. CHEN, RITA F. REDBERG. 2007. Echocardiographic Evaluation of the Patient with a Systemic Embolic Event. , 969-998.
CrossRef611
A Sultan, JF Thuan, A Avignon. (2006) Primary prevention of cardiovascular events and type 2 diabetes. Diabetes & Metabolism 32:6, 559-567
CrossRef612
Hans-Christoph Diener. (2006) NSA guidelines for management of transient ischaemic attacks. The Lancet Neurology 5:12, 996-997
CrossRef613
Udaya S Tantry, Kevin P Bliden, Paul A Gurbel. (2006) Prasugrel. Expert Opinion on Investigational Drugs 15:12, 1627-1633
CrossRef614
Pierre Fayad. (2006) Secondary prevention measures after a stroke—should they target stroke or heart disease?. Nature Clinical Practice Neurology 2:12, 646-647
CrossRef615
(2006) Scientific surgery. British Journal of Surgery 93:12, 1567-1567
CrossRef616
Mohamed Jabaren, Devang Mahesh Desai, Abdulrahman Arabi, Gautam Kareti, Carol Chen-Scarabelli, Howard Seeman Rosman. (2006) Effect of Clopidogrel Plus Aspirin on ST Segments in Patients With ST-Elevation Acute Myocardial Infarction. The American Journal of Cardiology 98:11, 1435-1438
CrossRef617
Christopher P. Cannon, Deepak L. Bhatt. (2006) Clinical Trials Update from the Annual Scientific Session of the American College of Cardiology 2006. The American Journal of Cardiology 98:12, S36-S41
CrossRef618
Glen E Cooke, Pascal J Goldschmidt-Clermont. (2006) The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opinion on Drug Safety 5:6, 815-826
CrossRef619
Robert D. Ecker, Elad I. Levy, Eric Sauvageau, Ricardo A. Hanel, L Nelson Hopkins. (2006) Current Concepts in the Management of Intracranial Atherosclerotic Disease. Neurosurgery 59:SUPPLEMENT, S3-210-S3-218
CrossRef620
E. T. H. YEH, B. V. KHAN. (2006) The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. Journal of Thrombosis and Haemostasis 4:11, 2308-2316
CrossRef621
M. Grebe. (2006) Gerinnungsaktive Medikamente zur Sekundärprophylaxe bei pAVK. Gefässchirurgie 11:5, 341-346
CrossRef622
Richard C. Becker. (2006) Biosignatures in thrombotic disorders. Journal of Thrombosis and Thrombolysis 22:2, 157-158
CrossRef623
JOSEPH P. CARROZZA. (2006) Duration of Clopidogrel Therapy with Drug-Eluting Stents. Journal of Interventional Cardiology 19:s5, S40-S46
CrossRef624
Naveed Akhtar, Dirk Deleu, Ashfaq Shuaib. (2006) Antithrombotic therapy in secondary stroke prevention. Aging Health 2:5, 787-797
CrossRef625
Robert J Adams. (2006) Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?. Nature Clinical Practice Neurology 2:10, 532-533
CrossRef626
PAUL A. GURBEL, UDAYA S. TANTRY. (2006) Aspirin and Clopidogrel Resistance: Consideration and Management. Journal of Interventional Cardiology 19:5, 439-448
CrossRef627
Rohan Jagathesan, Stuart D Rosen, Rodney A Foale, Paolo G Camici, Eugenio Picano. (2006) Effects of Long-Term Oral Dipyridamole Treatment on Coronary Microcirculatory Function in Patients With Chronic Stable Angina: A Substudy of the Persantine In Stable Angina (PISA) Study. Journal of Cardiovascular Pharmacology 48:3, 110-116
CrossRef628
Philip R. Liebson. (2006) CHARISMA and TROPHY. Preventive Cardiology 9:4, 235-238
CrossRef629
Florian B. Mayr, Bernd Jilma. (2006) Current developments in anti-platelet therapy. Wiener Medizinische Wochenschrift 156:17-18, 472-480
CrossRef630
P. Ambrosi, P. Villani, G. Bouvenot. (2006) Antiplatelet therapy for primary prevention in diabetes. Diabetes & Metabolism 32, 2S52-2S56
CrossRef631
Peter Elwood, Marcus Longley, Gareth Morgan. (2006) My health: whose responsibility? Low-dose aspirin and older people. Expert Review of Cardiovascular Therapy 4:5, 755-764
CrossRef632
Pierre Théroux, Benoît Labarthe. (2006) Coping with new challenges in acute coronary syndromes. Canadian Journal of Cardiology 22, 13C-20C
CrossRef633
Karen E Thomas, Duane S Pinto. (2006) Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?. Nature Clinical Practice Cardiovascular Medicine 3:8, 416-417
CrossRef634
(2006) Clopidogrel for the Prevention of Atherothrombotic Events. New England Journal of Medicine 355:4, 418-421
Full Text635
Paul A Gurbel, Udaya S Tantry. (2006) Drug Insight: clopidogrel nonresponsiveness. Nature Clinical Practice Cardiovascular Medicine 3:7, 387-395
CrossRef636
Robert P. Giugliano, Eugene Braunwald. (2006) The Year in Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 48:2, 386-395
CrossRef637
Dennis L. DeSilvey. (2006) Lost in Translation: What Have We Learned From the CHARISMA Trial?. The American Journal of Geriatric Cardiology 15:4, 260-261
CrossRef638
D. Fosburgh. (2006) Aspirin and Clopidogrel Resistance. Mayo Clinic Proceedings 81:7, 989-989
CrossRef639
Dalton S. McLean, Christopher P. Cannon. (2006) The Clinical Potential of a Point-of-Care Assay to Assess Interindividual Variability in Platelet Aggregation Among Patients Taking Clopidogrel. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 5:2, 103-113
CrossRef640
Antònia Agustí, Montserrat Bosch. (2006) Prevención de la enfermedad aterotrombótica con la combinación de dos antiagregantes plaquetarios. Medicina Clínica 127:4, 153-155
CrossRef641
Gabriel B. Habib. (2006) Prevention of vascular events in patients with cerebrovascular disease: Efficacy and appropriate duration of antiplatelet therapy. Clinical Cardiology 29:6, 244-248
CrossRef642
David H. Fitchett, Bjug Borgundvaag, Warren Cantor, Eric Cohen, Sanjay Dhingra, Stephen Fremes, Milan Gupta, Michael Heffernan, Heather Kertland, Mansoor Husain, Anatoly Langer, Eric Letovsky, Shaun G. Goodman. (2006) Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm. Canadian Journal of Cardiology 22:8, 663-677
CrossRef643
Freek WA Verheugt. (2006) Good old warfarin for stroke prevention in atrial fibrillation. The Lancet 367:9526, 1877-1878
CrossRef644
John A. Ambrose. (2006) Myocardial Ischemia and Infarction. Journal of the American College of Cardiology 47:11, D13-D17
CrossRef645
Rhondalyn C. McLean, Emile R. Mohler, Roger S. Blumenthal. (2006) Vascular Disease, Hypertension, and Prevention. Journal of the American College of Cardiology 47:11, D3-D8
CrossRef646
Helmi L. Lutsep. (2006) MATCH Results: Implications for the Internist. The American Journal of Medicine 119:6, 526.e1-526.e7
CrossRef647
(2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. The Lancet 367:9523, 1665-1673
CrossRef648
Bo Norrving. (2006) Dipyridamole with aspirin for secondary stroke prevention. The Lancet 367:9523, 1638-1639
CrossRef649
Lagakos, Stephen W., . (2006) The Challenge of Subgroup Analyses — Reporting without Distorting. New England Journal of Medicine 354:16, 1667-1669
Full Text650
Pfeffer, Marc A., Jarcho, John A., . (2006) The Charisma of Subgroups and the Subgroups of CHARISMA. New England Journal of Medicine 354:16, 1744-1746
Full Text651
James J Ferguson. (2006) The Role of Oral Antiplatelet Agents in Atherothrombotic Disease. American Journal of Cardiovascular Drugs 6:3, 149-157
CrossRef
- Letters
